Methods for determining a level of a therapeutic protein comprising an antigen binding site specifically binding to a peptide major histocompatibility complex (MHC) complex and Anti-idiotypic antibodies binding thereto
The method addresses the challenge of high background signals in therapeutic protein quantification by using anti-idiotypic antibodies to detect peptide-MHC complexes, achieving reliable and sensitive protein level determination for clinical applications.
Patent Information
- Application Number
- PCT/EP2026/063444
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Existing methods for determining the level of therapeutic proteins, particularly those binding to peptide-MHC complexes, suffer from high background signals and suboptimal performance in human blood samples, necessitating the development of more reliable and accurate quantification techniques for clinical applications.
A method involving incubation of a sample with a peptide-MHC complex and anti-idiotypic antibodies specific to the therapeutic protein, followed by detection of the bound anti-idiotypic antibodies to determine the protein level, utilizing anti-idiotypic antibodies and anti-idiotypic antibody fragments to enhance specificity and sensitivity.
The method reduces signal background while maintaining high specificity and sensitivity, enabling reliable quantification of therapeutic proteins suitable for pharmacokinetic assays in clinical trials.
Smart Images

Figure IMGF000055_0001_TABLE 
Figure IMGF000056_0001_TABLE 
Figure IMGF000057_0001_TABLE
Abstract
Description
[0001] Immatics Biotechnologies GmbH
[0002] Our ref.: 1017-113 PCT
[0003] Methods for determining a level of a therapeutic protein comprising an antigen binding site specifically binding to a peptide major histocompatibility complex (MHC) complex and anti- idiotypic antibodies binding thereto
[0004] The present invention relates to methods for determining a level of a therapeutic protein in a sample, wherein the therapeutic protein comprises an antigen binding site A specifically binding to a peptide that is in complex with a major histocompatibility complex (MHC) protein, and an antigen binding site B. The invention further relates to anti-idiotypic antibodies and the fragments thereof binding to the antigen binding sites and to the methods using the same.
[0005] Methods for quantifying therapeutic proteins are used in many contexts. One of the most important use of such a method is the pharmacokinetic (PK) assay, which is essential in drug development and pharmacology. The PK assay needs to be accurate and reliable in order to be used in clinical research. Their primary purpose is to understand how a drug behaves in the subject. The PK assays are thus important tools in pre- and post-regulatory approval. Multispecific proteins specifically binding to peptide-MHC complexes are promising class of medicaments, in particular for patients suffering from cancer and / or tumorous disease. Immune assays employing a sandwich ELISA had been used to quantify bispecific proteins in PK analyses (e.g. in Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific Ab targeting human claudin 6, Stadler et al., Sci. Transl. Med. 16, eadl2720 (2024)). However, there remains a need for reliable and improved methods and means for determining a level of a therapeutic protein. Accordingly, the technical problem underlying the present invention is the provision of reliable methods and means for determining a level of a therapeutic protein in a sample of a patient. The technical problem is solved and the above-mentioned needs are addressed by the provision of the embodiments characterized in the claims and as provided herein below.
[0006] The inventors found that using the classical sandwich ELISA for determining a level of a therapeutic protein led to high background signals and suboptimal performance for human blood samples. As documented in the appended examples, the inventors surprisingly demonstrated that the herein provided methods reduce the signal background, while at the same time maintain high specificity and sensitivity. Thus, the herein provided embodiments provide methods and means that can be used within clinical trials settings, e.g. in a PK assay. As detailed in the examples, the use of the methods as claimed provided reliable quantification of the therapeutic protein that allows reliable PK assessments. Furthermore, the examples demonstrate that the anti-idiotypic antibodies provided herein can be beneficially be used in the herein provided methods. In addition, the herein provided anti-idiotypic antibodies can beneficially be used inthe herein provided methods and in classical sandwich ELISAs as demonstrated below. Accordingly, the herein provided means and methods solve the underlying technical problem.
[0007] The invention relates in particular to the following items:
[0008] 1. A method for determining a level of a therapeutic protein in a sample,
[0009] wherein the therapeutic protein comprises
[0010] (i) an antigen binding site A specifically binding to a peptide that is in complex with a major histocompatibility complex (MHC) protein, and
[0011] (ii) an antigen binding site B, and
[0012] wherein the method comprises
[0013] a) incubating the sample comprising the therapeutic protein with the peptide-MHC complex specifically binding to the antigen binding site A of the therapeutic protein, b) incubating the therapeutic protein bound to the peptide-MHC complex with an anti- idiotypic antibody or fragment(s) thereof specifically binding to the antigen binding site B of the therapeutic protein, and
[0014] c) detecting the anti-idiotypic antibody or the fragment(s) thereof bound to the therapeutic protein and thereby determining the level of the therapeutic protein in the sample.
[0015] 2. The method of item 1, wherein the sample is from a subject or a group of subjects that was or is to be administered with the therapeutic protein.
[0016] 3. The method of item 1 or 2, wherein the antigen binding site B is different from the antigen binding site A.
[0017] 4. The method of any one of items 1 to 3, wherein the sample is obtained from a subject administered with the therapeutic protein.
[0018] 5. The method of any one of items 1 to 4, wherein the sample is a blood, urine or saliva sample, in particular the sample is serum, or plasma.
[0019] 6. The method of any one of items 1 to 5, wherein the peptide-MHC complex is a peptide- MHC complex monomer.
[0020] 7. The method of any one of items 1 to 6, wherein the peptide-MHC complex specifically binding to the therapeutic protein is immobilized on a solid phase, preferably a plate or resin, more preferably on a streptavidin-coated plate for multiplexing.The method of item 7, wherein the peptide-MHC complex is immobilized in a concentration of about 0.66 pg / ml, and / or the method of any one of items 1 to 7, wherein the incubating of step b) of the anti-idiotypic antibody specifically binding to the antigen binding site B is at a concentration of about 1 pg / ml.
[0021] The method of any one of items 1 to 8, wherein the sample is used with a minimum required dilution of 1: 4.
[0022] The method of any one of items 1 to 9, wherein the incubating of step a) is about lh at room temperature, and wherein the incubating of step b) is about 5 min at room temperature.
[0023] The method of any one of items 1 to 10, wherein subsequent to steps a), and / or b) the non-bound fraction is removed by washing.
[0024] The method of any one of items 1 to 11, wherein the anti-idiotypic antibody or the fragment(s) specifically binding to the antigen binding site B comprises a labeling reagent.
[0025] The method of item 12, wherein the labeling reagent is a labeling reagent selected from the group consisting of chemiluminescent labels, preferably, N-hydroxysuccinimide (NHS) ester, more preferably a SULFO-tag, fluorescent dyes, such as FITC, Alexa Fluor dyes, and Cy dyes, enzymatic labels, such as, horseradish peroxidase (HRP) and alkaline phosphatase (AP), biotin, and radioactive isotopes.
[0026] The method of any one of items 1 to 13, wherein the method is performed on an immunoassay platform, preferably a platform with multiplexing and high throughput capabilities, e.g. an Meso Scale discovery (MSD) platform.
[0027] The method of any one of items 1 to 14, wherein the method is used for determining the pharmacokinetic of the therapeutic protein.
[0028] The method of any one of items 1 to 15, wherein the therapeutic protein comprises immunoglobulin (Ig) domains, preferably wherein the therapeutic protein comprises an antigen binding site that is derived from a TCR, or is a TCR or fragment(s) thereof, and / or wherein the therapeutic protein comprises an antigen binding site that is derived from an antibody, or is an antibody or fragment(s) thereof.17. The method of any one of items 1 to 16, wherein the antigen binding site A is derived from a TCR, or is a TCR or fragment(s) thereof, or is derived from an antibody, or is an antibody or fragment(s) thereof.
[0029] 18. The method of item 16 or 17, wherein the TCR or the fragment(s) thereof is / are from an a / P TCR, or a y / 5 TCR.
[0030] 19. The method of any one of items 1 to 18, wherein the antigen binding site A comprises or is formed from a T cell receptor (TCR) alpha variable domain (Va) and a TCR beta variable domain (VP).
[0031] 20. The method of any one of items 1 to 19, wherein the MHC protein is an HLA protein, preferably HLA-A, more preferably HLA-A*02.
[0032] 21. The method of any one of items 1 to 20, wherein the therapeutic protein is a soluble protein.
[0033] 22. The method of any one of items 1 to 21, wherein the therapeutic protein is a multispecific antigen binding protein, in particular a bispecific antigen binding protein.
[0034] 23. The method of any one of items 1 to 22, wherein the antigen-binding site A binds to a MAGEA4 / 8 derived peptide bound to a major histocompatibility complex (MHC) protein or wherein the antigen-binding site A binds to a PRAME derived peptide bound to an MHC.
[0035] 24. The method of any one of items 4 to 23, wherein the subject suffers from a disease and / or disorder, in particular from cancer and / or a tumorous disease.
[0036] 25. The method of item 24, wherein the subject suffers from a cancer being positive for the peptide that is specifically bound by the antigen binding site A.
[0037] 26. The method of item 24 or 25, wherein the subject suffers from a PRAME-positive cancer and / or from a MAGEA4 / 8 positive cancer.
[0038] 27. The method of any one of items 24 to 26, wherein the cancer is selected from the group consisting of adrenocortical carcinoma, bladder cancer, in particular bladder carcinoma, brain tumor, in particular glioblastoma, primary brain cancer, or atypical meningioma, breast cancer, in particular triple-negative breast cancer or breast carcinoma, cervical carcinoma, in particular cervical squamous cell carcinoma or endocervicaladenocarcinoma, cholangiocellular carcinoma, colorectal cancer, in particular colon cancer, endometrial cancer, in particular uterine carcinoma or uterine carcinosarcoma, epithelial cancer of the larynx, esophageal carcinoma, fallopian tube cancer, gallbladder cancer, gastro-intestinal cancer, germ cell tumor, head and neck cancer, in particular head and neck adenocarcinoma, or head and neck squamous cell carcinoma, hepatocellular carcinoma, leukemia, in particular acute myeloid leukemia or chronic lymphocytic leukemia, lung cancer, in particular small cell lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma, non-small cell lung squamous cell carcinoma (sqNSCLC), or large cell carcinoma of the lung, lymphoma, in particular extranodal T / NK-cell lymphoma, non-Hodgkin lymphoma, or H. pylori-induced MALT non-Hodgkin lymphoma, malignant peripheral nerve sheath tumors, melanoma, in particular amelanotic melanoma, uveal melanoma, or cutaneous melanoma, mesothelioma, oral cavity carcinomas, oral squamous carcinoma, ovarian cancer, in particular epithelial ovarian cancer, serous ovarian cancer, ovarian carcinoma or ovarian carcinosarcoma, papillary thyroid carcinoma, primary peritoneal cancer, in particular restricted to serous, clear cell, and endometrioid subtypes, prostate cancer, renal cancer, in particular renal carcinoma, in particular renal clear cell carcinoma, renal papillary cell carcinoma, salivary duct carcinoma, sarcoma, in particular Ewing's sarcoma, fibrosarcoma, liposarcoma, osteosarcoma, or synovial sarcoma, testicular cancer, in particular testicular germ cell tumor, thymoma, urothelial carcinoma and uterine carcinoma.
[0039] 28. The method of any one of items 24 to 27, wherein the cancer is selected from the group consisting of (advanced and / or metastatic) cutaneous melanoma, uveal melanoma, gynecologic cancers such as endometrial carcinoma including uterine carcinosarcoma, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer restricted to serous, clear cell, and endometrioid subtypes, synovial sarcoma, and sqNSCLC.
[0040] 29. The method of any one of items 24 to 28, wherein the cancer is selected from the group consisting melanoma and ovarian cancer, preferably wherein the cancer is selected from the group consisting of (metastatic) cutaneous melanoma, (metastatic) uveal melanoma, and (metastatic) ovarian cancer.
[0041] 30. The method of any one of items 1 to 29, wherein the antigen binding site B specifically binds to a cell surface antigen of a human immune cells, preferably T cells or natural killer (NK) cells.31. The method of any one of items 1 to 30, wherein the antigen binding site B specifically binds to an antigen selected from the group consisting of CD2, CD3, in particular CD3y, CD36, and / or CD3E, CD4, CD5, CD7, CD8, CD10, CDllb, CDllc, CD14, CD16, CD18, CD22, CD25, CD28, CD32a, CD32b, CD33, CD41, CD41b, CD42a, CD42b, CD44, CD45RA, CD49, CD55, CD56, CD61, CD64, CD68, CD69, CD89, CD90, CD94, CD95, CD117, CD123, CD125, CD134, CD137, CD152, CD163, CD193, CD203c, CD235a, CD278, CD279, CD287, Ly-6.2C, Mell4, Nkp46, NKG2D, GITR, FCERI, TCRa / p, TCRy / 6, HLA-DR and 4-1 BB, or combinations thereof.
[0042] 32. The method of any one of items 1 to 31, wherein the antigen binding site B specifically binds to an a / |3 T cell receptor (TCR) / CD3 complex.
[0043] 33. The method of any one of items 1 to 32, wherein the therapeutic protein comprises a variable domain VH comprising a CDRH1, a CDRH2 and a CDRH3, and a VL comprising a CDRL1, a CDRL2, and a CDRL3, wherein CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 form an antigen binding site B.
[0044] 34. The method of any one of items 1 to 33, wherein the antigen binding site B of the therapeutic protein comprises a VH and a VL,
[0045] wherein the VH comprises
[0046] (a) a CDRH1 comprising the amino acid sequence of SEQ ID NO: 3;
[0047] (b) a CDRH2 comprising the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 5, and
[0048] (c) a CDRH3 comprising the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 7, and
[0049] wherein the VL comprises
[0050] (a) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 8,
[0051] (b) a CDRL2 comprising the amino acid sequence of SEQ ID NO: 9, and
[0052] (c) a CDRL3 comprising the amino acid sequence of SEQ ID NO: 10;
[0053] and optionally wherein each of the CDRH1, the CDRH2 and the CDRH3,
[0054] and / or the CDRL1, CDRL2, and CDRL3 comprises up to three amino acid substitutions.
[0055] 35. The method of any one of items 33 or 34, wherein the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 11, 12, 13 and 14, or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NOs: 11, 12, 13 or 14, and preferably comprising the CDRH1, CDRH2, and CDRH3 according to SEQ ID Nos: 3, 4 and 6; or to SEQ ID Nos: 3, 5 and 6; or to SEQ ID Nos: 3, 5 and 7; or to SEQ ID Nos: 3, 4 and 6, respectively; andwherein the VL comprises an amino acid sequence of SEQ ID NO: 15 or SEQ ID NO: 16, or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 15, and preferably comprising the CDRL1, CDRL2, and CDRL3 according to SEQ ID Nos: 8, 9 and 10, respectively;
[0056] and optionally wherein each of said CDRH1, CDRH2 and CDRH3, and / or said CDRL1, CDRL2 and CDRL3 comprises up to three amino acid substitutions.
[0057] The method of any one of items 1 to 35, wherein the antigen binding site B comprises (i) a VH that comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 11, 12, 13 and 14, or (an) antigen binding fragment(s) thereof, and (ii) a VL that comprises an amino acid sequence of SEQ ID NO: 15 or 16, or (an) antigen binding fragment(s) thereof.
[0058] The method of any one of items 1 to 35, wherein the antigen binding site A specifically binds to the peptide SEQ ID NO: 1 that is in complex with an MHC protein or to the peptide SEQ ID NO: 2 that is in complex with an MHC protein.
[0059] The method of any one of items 1 to 37, wherein the antigen binding site A comprises: a T cell receptor (TCR) alpha variable domain (Va) and a TCR beta variable domain (V|3), wherein the Va domain comprises
[0060] (i) a CDRal comprising the amino acid sequence according to SEQ ID NO: 17,
[0061] (ii) a CDRa2 comprising the amino acid sequence according to SEQ ID NO: 18, and (iii) a CDRa3 comprising the amino acid sequence according to SEQ ID NO: 19; and wherein the V|3 domain comprises
[0062] (i) a CDRpi comprising the amino acid sequence according to SEQ ID NO: 20,
[0063] (ii) a CDR|32 comprising the amino acid sequence according to SEQ ID NO: 21, and (iii) a CDR|33 comprising the amino acid sequence according to SEQ ID NO: 22; wherein one or more of CDRal, CDRa2, CDRa3, CDR|31, CDR|32 and CDR|33 may comprise one, two or three amino acid mutations, wherein the mutation may be a deletion, an insertion, or a substitution, preferably a conservative substitution.
[0064] The method of any one of items 1 to 38, wherein the antigen binding site A comprises a Va comprising or consisting of the amino acid sequence according to SEQ ID NO: 23 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 23 and comprising the CDRal, CDRa2, and CDRa3 according to SEQ ID NOs: 17, 18, and 19, respectively; anda VP comprising or consisting of the amino acid sequence according to SEQ ID NO: 24 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 24 and comprising the CDR|31, CDR|32, and CDR|33 according to SEQ ID NOs: 20, 21, and 23, respectively.
[0065] The method of any one of items 1 to 39, wherein the therapeutic protein comprises or consists of
[0066] a first polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 25 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 25 and comprising the CDRL1, CDRL2, CDRL3, CDR|31, CDR|32, and CDR|33 according to SEQ ID NOs: 8, 9, 10, 20, 21, and 22, respectively; and a second polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 26 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 26 and comprising the CDRal, CDRa2, CDRa3, CDRH1, CDRH2, and CDRH3 according to SEQ ID NOs: 17, 18, 19, 3, 5, and 6, respectively.
[0067] The method of any one of items 1 to 40, wherein the therapeutic protein comprises or consists of
[0068] a first polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 25, and
[0069] a second polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 26.
[0070] The method of any one of items 1 to 41, wherein the therapeutic protein comprises a modification of the N-terminal and / or C-terminal amino acid(s), preferably wherein the N-terminal glutamine is substituted by a pyro-glutamate.
[0071] The method of any one of items 1 to 37, wherein the antigen binding site A comprises: a T cell receptor (TCR) alpha variable domain (Va) and a TCR beta variable domain (V|3), wherein the Va domain comprises
[0072] (i) a CDRal comprising the amino acid sequence according to SEQ ID NO: 27,
[0073] (ii) a CDRa2 comprising the amino acid sequence according to SEQ ID NO: 28, and (iii) a CDRa3 comprising the amino acid sequence according to SEQ ID NO: 29; and wherein the V|3 domain comprises
[0074] (i) a CDRpi comprising the amino acid sequence according to SEQ ID NO: 30,
[0075] (ii) a CDR|32 comprising the amino acid sequence according to SEQ ID NO: 31, and (iii) a CDR|33 comprising the amino acid sequence according to SEQ ID NO: 32,wherein one or more of CDRal, CDRa2, CDRa3, CDR 1, CDR 2 and CDR 3 may comprise one, two or three amino acid mutations, wherein the mutation may be a deletion, an insertion, or a substitution, preferably a conservative substitution
[0076] 44. The method of item 43, wherein the antigen binding site A comprises:
[0077] a Va comprising or consisting of the amino acid sequence according to SEQ ID NO: 33 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 33 and comprising the CDRal, CDRa2, and CDRa3 according to SEQ ID NOs: 27, 28, and 29, respectively; and
[0078] a VP comprising or consisting of the amino acid sequence according to SEQ ID NO: 34 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 34 and comprising the CDR|31, CDR|32, and CDR|33 according to SEQ ID NOs: 30, 31, and 32, respectively.
[0079] 45. The method of any one of items 43 to 44, wherein the therapeutic protein comprises or consists of
[0080] a first polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 35 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 35 and comprising the CDRL1, CDRL2, CDRL3, CDR|31, CDR|32, and CDR|33 according to SEQ ID NOs: 8, 9, 10, 30, 31, and 32, respectively; and a second polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 36 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 36 and comprising the CDRal, CDRa2, CDRa3, CDRH1, CDRH2, and CDRH3 according to SEQ ID NOs: 27, 28, 29, 3, 4, and 6, respectively.
[0081] 46. The method of any one of items 43 to 45, wherein the therapeutic protein comprises or consists of a first polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 35, and a second polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 36.
[0082] 47. The method of any one of items 1 to 46, wherein the therapeutic protein comprises or consists of a first polypeptide and a second polypeptide, wherein the first polypeptide and the second polypeptide of the therapeutic protein are covalently or non-covalently linked together.
[0083] 48. The method of any one of items 1 to 47, wherein the binding sites A and / or B are in the format selected from the group consisting of an antibody, a single chain fragmentvariable (scFv), disulfide-stabilized Fv (dsFv), Fab, Fab', F(ab')2, a nanobody, a DARPin, a Knottin, a diabody or oligomers thereof.
[0084] The method of any one of items 1 to 48, wherein the binding sites A and B are in the format of an scFv.
[0085] The method of any one of items 1 to 49, wherein the therapeutic protein comprises a single chain TCR (scTCR) and / or a single-chain bispecific antibody.
[0086] The method of any one of items 47 to 50, wherein a first polypeptide chain comprises a structure represented by formula:
[0087] V1-L1-V2 [I]
[0088] wherein VI is a first variable domain; V2 is a second variable domain; LI is a linker domain;
[0089] and wherein a second polypeptide chain comprises a structure represented by formula:
[0090] V3-L3-V4 [II]
[0091] wherein V3 is a third variable domain; V4 is a fourth variable domain; L3 is a linker; optionally wherein:
[0092] VI and V2 form the antigen binding site A and V3 and V4 form the antigen binding site B, or
[0093] VI and V2 form the antigen binding site B and V3 and V4 form the antigen binding site A, or
[0094] VI and V3 form the antigen binding site A and V2 and V4 form the antigen binding site B, or
[0095] VI and V3 form the antigen binding site B and V2 and V4 form the antigen binding site A, or
[0096] VI and V4 form the antigen binding site A and V2 and V3 form the antigen binding site B, or
[0097] VI and V4 form the antigen binding site B and V2 and V3 form the antigen binding site A, and
[0098] optionally, wherein the first polypeptide and the second polypeptide are covalently or non-covalently linked together.The method of item 51, wherein a first polypeptide chain comprises a structure represented by formula:
[0099] V1-L1-V2-L2-C1 [III]
[0100] wherein VI is a first variable domain; V2 is a second variable domain; LI and L2 are linkers; L2 may be present or absent; Cl is a constant domain or a dimerizing portion thereofand present or absent, preferably wherein ClisCLa light chain constant domain or a dimerizing portion thereof;
[0101] and wherein a second polypeptide chain comprises a structure represented by formula:
[0102] V3-L3-V4-L4-C2 [IV]
[0103] wherein V3 is a third variable domain; V4 is a fourth variable domain; L3 and L4 are linkers; L4 may be present or absent; C2 is a constant domain or a dimerizing portion thereof and is present or absent, preferably wherein C2 is CH a heavy chain constant domain or a dimerizing portion thereof; and wherein preferably
[0104] VI and V2 form the antigen binding site A and V3 and V4 form the antigen binding site B, or
[0105] VI and V2 form the antigen binding site B and V3 and V4 form the antigen binding site A, or
[0106] VI and V3 form the antigen binding site A and V2 and V4 form the antigen binding site B, or
[0107] VI and V3 form the antigen binding site B and V2 and V4 form the antigen binding site A, or
[0108] VI and V4 form the antigen binding site A and V2 and V3 form the antigen binding site B, or
[0109] VI and V4 form the antigen binding site B and V2 and V3 form the antigen binding site A, and
[0110] optionally, wherein the first polypeptide and the second polypeptide are covalently or non-covalently linked together.
[0111] The method of item 52, wherein the first polypeptide chain has a structure represented by the formula [V]:
[0112] V1-L1-V2-L2-C1-L5-FC1 [V]
[0113] and the second polypeptide chain has a structure represented by the formula [VI]:
[0114] V3-L3-V4-L4-C2-L6-FC2 [VI]wherein VI to V4, LI to L4, Cl and C2 are as defined in item 52 and wherein L5 and L6 are linkers and present or absent and FC1, and FC2 are Fc-domains and wherein FC1 and FC2 are the same or different.
[0115] 54. The method of item 53, wherein FC1 and / or FC2 comprises or consists of the amino acid sequence SEQ ID NO: 37 and / or SEQ ID NO: 38; and / or
[0116] wherein LI and L3 comprise or consist of the amino acid sequence SEQ ID NO: 39.
[0117] 55. An anti-idiotypic antibody or fragment(s) thereof comprising,
[0118] a VH comprising
[0119] (a) a CDRH1 comprising the amino acid sequence of SEQ ID NO: 40,
[0120] (b) a CDRH2 comprising the amino acid sequence of SEQ ID NO: 41,
[0121] (c) a CDRH3 comprising the amino acid sequence of SEQ ID NO: 42, and
[0122] a VL comprising
[0123] (a) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 43,
[0124] (b) a CDRL2 comprising the amino acid sequence of SEQ ID NO: 44,
[0125] (c) a CDRL3 comprising the amino acid sequence of SEQ ID NO: 45,
[0126] and optionally wherein each of the CDRH1, the CDRH2 and the CDRH3, and the CDRL1, CDRL2, and CDRL3 comprises up to three amino acid substitutions.
[0127] 56. The anti-idiotypic antibody or the fragment(s) thereof of item 55, wherein the anti- idiotypic antibody or fragment(s) thereof comprises
[0128] a VL comprising or consisting of the amino acid sequence according to SEQ ID NO: 46 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 46 and comprising the CDRL1, CDRL2, and CDRL3 according to SEQ ID NOs: 43, 44, and 45, respectively; and
[0129] a VH comprising or consisting of the amino acid sequence according to SEQ ID NO: 47 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 47 and comprising the CDRH1, CDRH2, and CDRH3 according to SEQ ID NOs: 40, 41, and 42, respectively.
[0130] 57. The anti-idiotypic antibody or the fragment(s) thereof of item 55 or 56, wherein the anti- idiotypic antibody or fragment(s) thereof comprises,
[0131] a first polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 48 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 48 and comprising the CDRL1, CDRL2, and CDRL3 according to SEQ ID NOs: 43, 44, and 45, respectively; anda second polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 49 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 49and comprising the CDRH1, CDRH2, and CDRH3 according to SEQ ID NOs: 40, 41, and 42, respectively.
[0132] The anti-idiotypic antibody or the fragment(s) thereof of any one of items 55 to 57, wherein the anti-idiotypic antibody or the fragment(s) thereof specifically bind(s) to the antigen binding site B, wherein the antigen binding site B comprises a VH comprising (a) a CDRH1 comprising the amino acid sequence of SEQ ID NO: 3;
[0133] (b) a CDRH2 comprising the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 5, and
[0134] (c) a CDRH3 comprising the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 7, and
[0135] and a VL comprises
[0136] (a) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 8,
[0137] (b) a CDRL2 comprising the amino acid sequence of SEQ ID NO: 9, and
[0138] (c) a CDRL3 comprising the amino acid sequence of SEQ ID NO: 10;
[0139] and optionally wherein each of the CDRH1, the CDRH2 and the CDRH3,
[0140] and / or the CDRL1, CDRL2, and CDRL3 comprises up to three amino acid substitutions.
[0141] The anti-idiotypic antibody or the fragment(s) thereof of any one of items 55 to 58, wherein the anti-idiotypic antibody or the fragment(s) thereof specifically bind(s) to the antigen binding site B, wherein the antigen binding site B comprises
[0142] (i) the VH comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 11, 12, 13 and 14, or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NOs: 11, 12, 13 or 14 and preferably comprising the CDRH1, CDRH2, and CDRH3 according to SEQ ID Nos: 3, 4 and 6; or to SEQ ID Nos: 3, 5 and 6; or to SEQ ID Nos: 3, 5 and 7; or to SEQ ID Nos: 3, 4 and 6, respectively; and
[0143] (ii) the VL comprising an amino acid sequence of SEQ ID NO: 15 or SEQ ID NO: 16, or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 15, and preferably comprising the CDRL1, CDRL2, and CDRL3 according to SEQ ID Nos: 8, 9 and 10, respectively;
[0144] and optionally wherein each of said CDRH1, CDRH2 and CDRH3, and said CDRL1, CDRL2 and CDRL3 comprises up to three amino acid substitutions.
[0145] The anti-idiotypic antibody or the fragment(s) thereof of any one of items 55 to 59, wherein the anti-idiotypic antibody or the fragment(s) thereof binds to an antigenbinding site B or the fragment(s) thereof that specifically binds to a cell surface antigen of a human immune cells, preferably? cells or natural killer (NK) cells, preferably to an a / p T cell receptor (TCR) / CD3 complex.
[0146] 61. The anti-idiotypic antibody or the fragment(s) thereof of any one of items 55 to 60, wherein the anti-idiotypic antibody or the fragment(s) thereof comprise(s) a labeling reagent.
[0147] 62. The method of any one of items 1 to 61, wherein the anti-idiotypic antibody or the fragment(s) thereof of any one of items 55 to 62 are used in step b) of item 1.
[0148] 63. An anti-idiotypic antibody or fragment(s) thereof comprising,
[0149] a VH comprising
[0150] (a) a CDRH1 comprising the amino acid sequence of SEQ ID NO: 50,
[0151] (b) a CDRH2 comprising the amino acid sequence of SEQ ID NO: 51,
[0152] (c) a CDRH3 comprising the amino acid sequence of SEQ ID NO: 52, and
[0153] a VL comprising
[0154] (a) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 53,
[0155] (b) a CDRL2 comprising the amino acid sequence of SEQ ID NO: 54,
[0156] (c) a CDRL3 comprising the amino acid sequence of SEQ ID NO: 55;
[0157] or
[0158] a VH comprising
[0159] (a) a CDRH1 comprising the amino acid sequence of SEQ ID NO: 56,
[0160] (b) a CDRH2 comprising the amino acid sequence of SEQ ID NO: 57,
[0161] (c) a CDRH3 comprising the amino acid sequence of SEQ ID NO: 58, and
[0162] a VL comprising
[0163] (a) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 59,
[0164] (b) a CDRL2 comprising the amino acid sequence of SEQ ID NO: 60,
[0165] (c) a CDRL3 comprising the amino acid sequence of SEQ ID NO: 61;
[0166] and optionally wherein each of the CDRH1, the CDRH2 and the CDRH3, and the CDRL1, CDRL2, and CDRL3 comprises up to three amino acid substitutions.
[0167] 64. The anti-idiotypic antibody or the fragment(s) thereof of item 63, the anti-idiotypic antibody or fragment(s) thereof comprising,
[0168] a VL comprising or consisting of the amino acid sequence according to SEQ ID NO: 62 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 62 and comprising the CDRL1, CDRL2, and CDRL3 according to SEQ ID NOs: 53, 54, and 55, respectively; anda VH comprising or consisting of the amino acid sequence according to SEQ ID NO: 63 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 63 and comprising the CDRH1, CDRH2, and CDRH3 according to SEQ ID NOs: 50, 51, and 52, respectively; or
[0169] a VL comprising or consisting of the amino acid sequence according to SEQ ID NO: 64 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 64 and comprising the CDRL1, CDRL2, and CDRL3 according to SEQ ID NOs: 59, 60, and 61, respectively; and
[0170] a VH comprising or consisting of the amino acid sequence according to SEQ ID NO: 65 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 65 and comprising the CDRH1, CDRH2, and CDRH3 according to SEQ ID NOs: 56, 57, and 58, respectively.
[0171] The anti-idiotypic antibody or the fragment(s) thereof of any one of items 63 to 65, wherein the anti-idiotypic antibody or the fragment(s) thereof binds to a TCR or fragment(s) thereof that binds to a peptide that is in complex with a major histocompatibility complex (MHC) protein.
[0172] The anti-idiotypic antibody or the fragment(s) thereof of any one of items 63 to 65, wherein the anti-idiotypic antibody or the fragment(s) thereof bind(s) to the antigen binding site A, wherein the antigen binding site A specifically binds to the peptide SEQ ID NO: 1 (MAG-003) that is in complex with an MHC protein.
[0173] The anti-idiotypic antibody or the fragment(s) thereof of any one of items 63 to 66, wherein the anti-idiotypic antibody or the fragment(s) thereof specifically bind(s) to the antigen binding site A, wherein the antigen binding site A comprises
[0174] a T cell receptor (TCR) alpha variable domain (Va) and a TCR beta variable domain (V|3), wherein the Va domain comprises
[0175] (i) a CDRal comprising the amino acid sequence according to SEQ ID NO: 17,
[0176] (ii) a CDRa2 comprising the amino acid sequence according to SEQ ID NO: 18, and (iii) a CDRa3 comprising the amino acid sequence according to SEQ ID NO: 19; and wherein the V|3 domain comprises
[0177] (i) a CDRpi comprising the amino acid sequence according to SEQ ID NO: 20,
[0178] (ii) a CDR|32 comprising the amino acid sequence according to SEQ ID NO: 21, and (iii) a CDR|33 comprising the amino acid sequence according to SEQ ID NO: 22; wherein one or more of CDRal, CDRa2, CDRa3, CDR|31, CDR|32 and CDR|33 may comprise one, two or three amino acid mutations, wherein the mutation may be a deletion, an insertion, or a substitution, preferably a conservative substitution68. The anti-idiotypic antibody or the fragment(s) thereof of any one of items 63 to 67, wherein the antigen binding site A comprises
[0179] a Va comprising or consisting of the amino acid sequence according to SEQ ID NO: 23 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 23 and comprising the CDRal, CDRa2, and CDRa3 according to SEQ ID NOs: 17, 18, and 19, respectively; and
[0180] a VP comprising or consisting of the amino acid sequence according to SEQ ID NO: 24 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 24 and comprising the CDR|31, CDR|32, and CDR|33 according to SEQ ID NOs: 20, 21, and 23, respectively.
[0181] 69. The anti-idiotypic antibody or the fragment(s) thereof of any one of items 63 to 68, wherein the anti-idiotypic antibody or the fragment(s) thereof specifically bind(s) to a therapeutic protein comprising or consisting of
[0182] a first polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 25 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 25 and comprising the CDRL1, CDRL2, CDRL3, CDR|31, CDR|32, and CDR|33 according to SEQ ID NOs: 8, 9, 10, 20, 21, and 22, respectively; and a second polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 26 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 26 and comprising the CDRal, CDRa2, CDRa3, CDRH1, CDRH2, and CDRH3 according to SEQ ID NOs: 17, 18, 19, 3, 5, and 6, respectively.
[0183] 70. The anti-idiotypic antibody or the fragment(s) thereof of any one of items 63 to 69, wherein the therapeutic protein comprises a modification of the N-terminal and / or C- terminal amino acid(s), preferably wherein the N-terminal glutamine is substituted by a pyro-glutamate.
[0184] 71. The anti-idiotypic antibody or the fragment(s) thereof of any one of items 63 to 70, wherein the anti-idiotypic antibody or the fragment(s) thereof comprise(s) a labeling reagent.
[0185] 72. Use of the anti-idiotypic antibody or the fragment(s) thereof of any one of items 55 to 71 in determining a level of a protein comprising the antigen binding site A and / or the antigen binding site B.
[0186] 73. A nucleic acid or nucleic acids encoding the anti-idiotypic antibodies of any one of items 55 to 71.A vector or vectors comprising the nucleic acid or nucleic acids of item 73.
[0187] A host cell comprising the nucleic acid or nucleic acids of item 73 or the vector(s) of item 74.
[0188] The host cell of item 75, wherein the host cell is a cell for recombinant expression, such as a Chinese Hamster Ovary (CHO) cell or a yeast cell.
[0189] A method of producing the anti-idiotypic antibodies of any one of items 55 to 71, comprising culture the host cell of item 75 or 76 under suitable conditions, and optionally isolating the anti-idiotypic antibody produced by the host cells.
[0190] An anti-idiotypic antibody as produced by the method of item 77.
[0191] A kit comprising
[0192] i) the anti-idiotypic antibodies of any one of items 55 to 62 or 78, and / or
[0193] ii) the anti-idiotypic antibodies of any one of items 55 to 62 or 78, and optionally iii) reagents for detecting, a solid phase coupled with the peptide MHC complex and / or a leaflet.
[0194] A method for determining a level of a therapeutic protein in a sample, wherein the anti-idiotypic antibody or the fragment(s) thereof of any one of the items 55 to 62, or 78, and / or the anti-idiotypic antibody or the fragment(s) thereof of any one of the items 63 to 70 are used in the method.
[0195] A method for determining a level of anti-drug antibodies against a therapeutic protein in a sample, wherein the anti-idiotypic antibody or the fragment(s) thereof of any one of the items 55 to 62, or 78 and / or the anti-idiotypic antibody or the fragment(s) thereof of any one of the items 63 to 70 are used in the method.
[0196] A method for determining a level of a therapeutic protein in a sample,
[0197] wherein the therapeutic protein comprises
[0198] (i) an antigen binding site A specifically binding to a peptide that is in complex with a major histocompatibility complex (MHC) protein, and
[0199] (ii) an antigen binding site B, and
[0200] wherein the method comprises
[0201] a) incubating the sample comprising the therapeutic protein with the anti-idiotypic antibody of any of items 55 to 62 specifically binding to the antigen binding site Bof the therapeutic protein; or with the anti-idiotypic antibody of any of items 63 to 70 specifically binding to the antigen binding site A of the therapeutic protein, b) incubating the therapeutic protein bound to the anti-idiotypic antibody with the anti-idiotypic antibody specifically binding to the other antigen binding site of the therapeutic protein that was not bound by the anti-idiotypic antibody in step a), and
[0202] c) detecting the anti-idiotypic antibody bound to the therapeutic protein and thereby determining the level of the therapeutic protein in the sample.
[0203] 83. The method of item 82, wherein the anti-idiotypic antibody used in step a) is used to immobilize the therapeutic protein on a solid phase, and wherein the anti-idiotypic antibody used in step b) is used in detecting the therapeutic protein.
[0204] 84. A method for determining a level of anti-drug antibodies against a therapeutic protein in a sample,
[0205] wherein the therapeutic protein comprises
[0206] (i) an antigen binding site A specifically binding to a peptide that is in complex with a major histocompatibility complex (MHC) protein, and
[0207] (ii) an antigen binding site B, and
[0208] wherein the method comprises
[0209] a) incubating the sample with (al) the therapeutic protein comprising a capturing reagent and (a2) the therapeutic protein comprising a labeling reagent, and b) detecting the therapeutic protein comprising the labeling reagent that is bound to the anti-drug antibody, and thereby determining the level of the anti-drug antibodies in the sample, and wherein the anti-idiotypic antibody of any one of items 55 to 62 or 63 to 70 is used as a control, in particular wherein the anti-idiotypic antibody of any one of items 55 to 62 is used.
[0210] In the following, the invention is described in more detail.
[0211] In a first aspect, the invention relates to a method for determining a level of a therapeutic protein in a sample, wherein the therapeutic protein comprises
[0212] (i) an antigen binding site A specifically binding to a peptide that is in complex with a major histocompatibility complex (MHC) protein, and
[0213] (ii) an antigen binding site B, and
[0214] wherein the method comprises
[0215] a) incubating the sample comprising the therapeutic protein with the peptide-MHC complex specifically binding to the antigen binding site A of the therapeutic protein,b) incubating the therapeutic protein bound to the peptide-MHC complex with an anti- idiotypic antibody or fragment(s) thereof specifically binding to the antigen binding site B of the therapeutic protein, and
[0216] c) detecting the anti-idiotypic antibody or the fragment(s) thereof bound to the therapeutic protein and thereby determining the level of the therapeutic protein in the sample.
[0217] The herein provided methods are in vitro methods that may particularly be used for determining the pharmacokinetics of a therapeutic protein.
[0218] The therapeutic protein herein used comprises an antigen binding site A specifically binding to a peptide that is in complex with a major histocompatibility complex (MHC) protein, and an antigen binding site B. Pharmacokinetics is typically used as the quantitative study of how drugs move into, through, and out of the body. The herein provided method can be used to assess the pharmacokinetics of the absorption, distribution, metabolism, and excretion (ADME) of the therapeutic protein in a subject. The term "determining the level" refers in particular embodiments to determining the presence, the amount, or the signal of the therapeutic protein. The herein provided methods may in particular be used to quantify the therapeutic protein in a sample. Thus, determining a level typically indicates the amount of the therapeutic protein in the sample or may refer to determine the concentration of the therapeutic protein in the sample. In particular, the methods may be used to determine the concentration of the therapeutic protein, e.g. to determine a level between the range of 0.1526 ng / ml and 156.25 ng / ml in the sample.
[0219] The herein provided methods may further comprise the step of obtaining the sample. In further embodiments, the sample is obtained from a subject administered with the therapeutic protein. The sample used in the herein provided methods is thus obtained from a subject or a group of subjects. The subject is particularly a human subject. In particular embodiments, the subject may suffer from cancer, tumorous disease, autoimmune disease, and / or an infectious disease. In particular, the subject may suffer from cancer and / or a tumorous disease or disorder. Autoimmune Diseases may include type 1 Diabetes, rheumatoid arthritis, multiple sclerosis. Infectious diseases may include HIV, or hepatitis B and C.
[0220] The herein provided methods are in vitro methods. The sample is then incubated according to herein described methods in the particular embodiments. The sample may also be obtained in a clinical site and the further steps of the methods can be conducted at a different site. The sample is usually a blood, urine or saliva sample, in particular the sample is a blood sample or parts thereof. In particular embodiments, the sample is serum, or plasma, preferably serum. The sample used in the herein provided methods may also be processed, e.g. the serum sampleobtained may be diluted, e.g. with a dilution of 1:1, 1:2, 1:3, 1:4, 1:5 or 1:10 or even more, preferably a minimum required dilution of 1: 4 is used, in particular in the PK assay.
[0221] The herein described methods, and means are particularly suitable for determining the level of a therapeutic protein that comprises (i) an antigen binding site A specifically binding to the peptide that is in complex with a major histocompatibility complex (MHC) protein, and (ii) an antigen binding site B. Accordingly, the therapeutic protein has at least two antigen binding sites. The antigen binding site A specifically binds to the peptide in complex with the MHC (peptide-MHC protein). The "Major Histocompatibility Complex" (MHC) is a set of cell surface proteins essential forthe acquired immune system to recognize molecules in vertebrates, which in turn determines histocompatibility. The human MHC is also called the HLA (human leukocyte antigen) complex (or just HLA). Thus, in a preferred embodiment, MHC is HLA. The MHC gene family is divided into three subgroups: class I, class II, and class III. Complexes of peptide and MHC class I molecules (MHC I) are usually recognized by CD8-positive T cells (CD8+ T cells) bearing the appropriate T cell receptor (TCR), whereas complexes of peptide and MHC class II molecules (MHC II) are usually recognized by CD4-positive helper-T cells (CD4+ T cells) bearing the appropriate TCR. The MHC class I HLA protein in the context of the present disclosure may be an HLA-A, HLA-B or HLA-C protein, suitably HLA-A protein, for example HLA-A*02. In the MHC class I dependent immune reaction, peptides not only have to be able to bind to certain MHC class I molecules expressed by tumor cells, they subsequently also have to be recognized by T cells bearing specific T cell receptors (TCR). The "peptide in a complex with an MHC protein", herein refers to an antigenic peptide that is non-covalently bound to an MHC. In particular, the antigenic peptide is located to a "peptide-binding groove" formed by the MHC. A complex of an MHC molecule and an antigenic peptide is herein also referred to as "peptide-MHC complex". The peptide-MHC complex is presented on a cell, e.g. a diseased or disordered cell, e.g. a cancer and / or tumor cell. In the context of the present invention, the peptide-MHC complex is over-presented on the cell surface of the subject compared to levels of said complex on the surface of cells in normal (healthy) tissue (also referred to as "healthy cells") or on the surface of control cells loaded with a different antigen presenting peptide or no peptide. Over-presented means that the peptide-MHC complex is present at a level at least 2-fold, preferably between 5-fold to 10-fold of the level present in healthy tissue or control cells. Thus, the subject may suffer from a disease and / or disorder associated with the peptide that is in complex with the MHC protein. The term "associated with the peptide" means that the peptide is over-presented. The subject is thus a subject in need of the therapeutic protein.
[0222] The antigen binding site A is specifically binding or recognizing one or more peptides with an overall length of from 8 to 100 amino acids, from 8 and 30 amino acids, from 8 to 16 amino acids, preferably from 8 and 14 amino acids, namely 8, 9, 10, 11, 12, 13, 14 amino acids, in case of the elongated class II binding peptides the length can also be 15, 16, 17, 18, 19, 20, 21 or 22 aminoacids. In a further embodiment, the antigen binding site A is specifically binding or recognizing one or more peptides with an overall length of from 8 to 12 amino acids, from 8 to 10 amino acids, from 9 to 15 amino acids, from 9 to 14 amino acids, from 9 to 13 amino acids, from 9 to 12 amino acids, from 9 to 11 amino acids; from 10 to 15 amino acids, from 10 to 14 amino acids, from 10 to 13 amino acids, or from 10 to 12 amino acids. Examples for peptides in complex with the MHC complex and to be recognized / bound can be found in the respective literature, and especially include the peptides as disclosed in US 18 / 490,581, US62 / 308944, US 9,717,774. Other suitable epitopes can be identified from databases, such as, for example, the Immune Epitope Database (available at www.iedb.org).
[0223] The term "antigen binding site" herein refers to a polypeptide or a complex of two or more polypeptides comprising an antigen binding site, wherein the antigen binding site is preferably derived from or share sequence homology with the variable regions of an antibody or of a TCR. Thus, the antigen binding site particularly comprises or forms an immunoglobulin (Ig) domain. As used herein, a "domain" may be any region of a protein, generally defined on the basis of sequence homologies and often referring to a specific structural or functional entity. In the context of variable domains of an antibody or a TCR, the domain comprises the antibody or TCR-derived CDR sequences as also disclosed below. The term "antigen" as used herein refers to a molecule or a portion of a molecule or complex that is capable of being bound by the antigen binding site. In particular embodiments, the therapeutic protein comprises two different antigen binding sites, i.e. the antigen binding site B is different from the antigen binding site A. This particularly means that the antigen binding site A specifically binds to a different antigen compared to the antigen binding site B, and / or that the antigen binding site A is structurally different compared to the antigen binding site B.
[0224] As used herein, the terms "polypeptide" or "protein" mean a macromolecule composed of one or more sequence(s) of amino acids. Thus, the therapeutic protein refers to a macromolecule composed of one or more sequence(s) of amino acids.
[0225] In particular embodiments, the antigen binding site A does not specifically bind to the antigen to which antigen binding site B binds or vice versa. Therefore, the therapeutic protein has two different binding specificities in particular embodiments. The term "specificity" in the context of the present invention denotes the capacity of an antigen binding protein to discriminate its antigen. An antigen binding protein / site is considered to be binding specifically to an antigen, if binding to said antigen occurs with a significantly higher affinity and / or higher functional avidity than the binding to another antigen or if said antigen binding site does not significantly bind to the different antigen. "Does not significantly bind" in this context typically means that in a binding assay, for example biolayer interferometry, a relative response signal for the binding of the antigen binding site / protein to one antigen was determined that is not higher than 30%, nothigher than 25%, not higher than 20%, not higher than 15%, preferably not higher than 20% of the signal obtained for the other antigen, preferably in the same experimental conditions.
[0226] The term "incubating" herein means contacting. Thus, incubating the sample with the peptide-MHC complex specifically binding to the antigen binding site A of the therapeutic protein of step a) means that the sample is brought in contact with the peptide-MHC complex. The antigen binding site A of the therapeutic protein then specifically binds to the peptide-MHC complex. Accordingly, a complex between the peptide-MHC complex and the therapeutic protein is formed. The therapeutic protein comprises an antigen binding site A specifically binding to a peptide in complex with the MHC protein. Thus, the peptide-MHC complex used in the incubation step a) specifically binds to the antigen binding site A. The conditions of incubation is not necessarily limited but should allow the binding of the therapeutic protein to the peptide-MHC complex. For example, the incubating of step a) may be about lh at room temperature, but may be longer or shorter. In particular embodiments, the peptide-MHC complex to which the therapeutic protein binds to in step a) is a peptide-MHC complex monomer. In this context, a monomer refers to a single MHC molecule bound to a peptide. An exemplary methods of providing peptide-MHC complexes as monomer is herein provided in the examples.
[0227] In a particular embodiment, the peptide-MHC complex specifically binding to the therapeutic protein is immobilized on a solid phase. More preferably, the peptide-MHC complex monomer specifically binding to the therapeutic protein is immobilized on a solid phase. For this purpose, the peptide-MHC complex monomers can be immobilized to a solid phase. For instance, the peptide-MHC complex is immobilized in a concentration of about 0.66 pg / ml. In particular embodiments, the streptavidin-coated solid phase is incubated with biotinylated peptide-MHC monomers. The incubation can be for 1 h at room temperature or over-night at 4°C. The nonbound fraction can be washed off by a washing buffer and the solid phase can be blocked, e.g. by bovine serum albumin.
[0228] The term "solid phase" denotes a non-fluid substance, and includes particles (including microparticles and beads) made from materials such as polymer, metal (paramagnetic, ferromagnetic particles), glass, and ceramic; gel substances such as silica, alumina, and polymer gels; capillaries, which may be made of polymer, metal, glass, and / or ceramic; zeolites and other porous substances; electrodes; microtiter plates; solid strips; and cuvettes, tubes or other spectrometer sample containers.
[0229] The solid phase may also be a stationary component, such as a tube, strip, cuvette or microtiter plate, or may be non-stationary components, such as beads and microparticles. A variety of microparticles that allow either non-covalent or covalent attachment of proteins and other substances may be used. Such particles include polymer particles such as polystyrene and poly (methylmethacrylate); gold particles such as gold nanoparticles and gold colloids; and ceramicparticles such as silica, glass, and metal oxide particles. See for example Martin, C.R., et al., Analytical Chemistry-News & Features, 70 (1998) 322A-327A, or Butler, J.E., Methods 22 (2000) 4-23, herein incorporated by reference. In particular embodiments, the solid phase is a a plate. Even more preferably, the solid phase is a plate for multiplexing. In even more preferred embodiments, the solid phase is an MSD plate, or Meso Scale Discovery plate. The MSD plate is used in electrochemiluminescence assays. These plates are designed for high-performance assays in both single and multiplex formats. They incorporate electrodes at the bottom of each well, enabling precise detection and measurement of various analytes. Herein, a MSD plate in 96-well and 384-well format can be used. As indicated above, the solid phase may be a streptavidin-coated plate, e.g. for multiplexing. In particular embodiments, a streptavidin-coated MSD plate is used. In particular embodiments, the method is performed on an immunoassay platform, preferably a platform with multiplexing and high throughput capabilities, e.g. an Meso Scale discovery (MSD) platform. As described herein above, the solid phase, e.g. covered by the peptide-MHC, may be further blocked and washed.
[0230] In the first aspect, the therapeutic protein bound to the peptide-MHC complex is incubated with an anti-idiotypic antibody or fragment(s) thereof specifically binding to the antigen binding site B of the therapeutic protein. In particular embodiments, the fraction non-bound to the peptide-MHC complex is washed off and only the complex of the therapeutic protein and the peptide-MHC complex is contacted with the anti-idiotypic antibody or fragments thereof specifically binding to the antigen binding site B. In general, step b) of the method of the first aspect, can also be that the therapeutic protein bound to the peptide-MHC complex is incubated with an anti-idiotypic antibody or fragment(s) thereof specifically binding to the therapeutic protein, and wherein preferably the anti-idiotypic antibody or fragment(s) thereof do not bind to the antigen binding site A. Thus, in further embodiments of the first aspect, the method for determining a level of a therapeutic protein in a sample comprises:
[0231] a) incubating the sample comprising the therapeutic protein with the peptide-MHC complex specifically binding to the antigen binding site A of the therapeutic protein,
[0232] b) incubating the therapeutic protein bound to the peptide-MHC complex with an anti- idiotypic antibody or fragment(s) thereof specifically binding to the therapeutic protein, and
[0233] c) detecting the anti-idiotypic antibody or the fragment(s) thereof bound to the therapeutic protein and thereby determining the level of the therapeutic protein in the sample.
[0234] In further preferred embodiments, the anti-idiotypic antibody or fragment(s) thereof specifically binding to the antigen binding site B of the therapeutic protein does / do not specifically bind to the antigen binding site A of therapeutic protein.In the first aspect, steps a) and b) may be performed subsequently, e.g. interspersed by washing steps, or may be performed simultaneously, wherein the sample is incubated with the peptide-MHC complex and the anti-idiotypic antibody or fragments thereof.
[0235] In particular embodiments of the first aspect, the incubating of step a) is about 0.5h, lh, 2,h or 4h at room temperature, preferably about lh, or for a longer time period if the incubation is conducted at 4°C, e.g. overnight. The proper incubation time could be adapted in view of the conditions in which the binding of the different components take place, e.g. the buffer ingredients or the temperature, or the components involved, and the skilled person knows how to adapt the incubation times or concentrations in view of the herein provided teaching. For example, the incubation time for step a) should be chosen in as such that the therapeutic protein binds to the peptide-MHC complex. The incubation time of step b) may preferably be about 5 min at room temperature, but may also be longer or shorter.
[0236] In further particular embodiments, the peptide-MHC complex is immobilized in a concentration of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.66, 0.7, 0.8, 0.9, 1.0, or 1.5 pg / ml, preferably about 0.66 pg / ml. Exemplary conditions (e.g. time) are herein below provided to immobilize the peptide-MHC on the solid phase. For example, a biotinylated p-MHC may be incubated with streptavidin coated solid phases. In further particular embodiments, the peptide-MHC complex is immobilized on the solid phase in a concentration of about 0.5 to about 1.5 pg / ml. Furthermore, in particular embodiments, the incubating of step b) of the anti-idiotypic antibody specifically binding to the antigen binding site B is at a concentration of about 0.5, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5 or 2 pg / ml, preferably about 1.0 pg / ml. In further particular embodiments, the incubating of step b) of the anti-idiotypic antibody specifically binding to the antigen binding site B is at a concentration of about 0.5 to 1.5.
[0237] As indicated above, the herein provided methods may particularly be used for determining the pharmacokinetics of a therapeutic protein. In further particular embodiments, the methods may be used to determine the distribution and elimination of the therapeutic protein, the potential immunogenicity of the therapeutic protein, the tl / 2, clearance, volume of distribution of the therapeutic protein, the Cmax, Ctrough, Tmax, Cavg of the therapeutic protein, the accumulation, steady state of the therapeutic protein, the population PK (PopPK) modelling, and / or PK-Pharmacodyamics (PD) analyses.
[0238] In particular embodiments, the therapeutic protein comprises immunoglobulin (Ig) domains, preferably wherein the therapeutic protein comprises an antigen binding site that is derived from a TCR, or is a TCR or fragment(s) thereof, and / or wherein the therapeutic protein comprises an antigen binding site that is derived from an antibody, or is an antibody or fragment(s) thereof. In further particular embodiments, the antigen binding site A is derived from a TCR, or is a TCR orfragment(s) thereof, or is derived from an antibody, or is an antibody or fragment(s) thereof. In further preferred embodiments, the antigen binding site A comprises or is formed from a T cell receptor (TCR) alpha variable domain (Va) and a TCR beta variable domain (VP). In most preferred embodiments, the MHC protein is an HLA protein, preferably HLA-A, more preferably HLA-A*02. In further most preferred embodiments, the therapeutic protein is a soluble protein.
[0239] The term "immunoglobulin (Ig) domain" in the context of the present invention refers to a protein domain that consists of a 2-layer sandwich of 7-9 antiparallel p-strands arranged in two P-sheets with a Greek key topology. Proteins containing Ig domains are subsumed into the immunoglobulin superfamily, including e.g. antibodies, T cell receptors (TCRs) and cell adhesion molecules. Examples of Ig domains are the variable and constant domains of antibodies and TCRs. The term "TCR" as used herein includes engineered TCRs. An engineered TCR may relate to a native TCR that comprises modification(s), e.g. amino acid substitution(s) and / or fragment(s) of a native or modified TCR. An "engineered TCR" may also be a protein resembling a native TCR, but comprising modifications in the variable and / or constant domains, e.g. a humanized TCR or a TCR with improved / altered characteristics (e.g. improved binding, heterodimerization or expression level), or may be a soluble TCR and / or a single-chain TCR, a monovalent, bivalent or multivalent TCR, a monospecific, bispecific or multispecific TCR, and / or a functional fragment of a TCR, or functional fragments of one or more TCRs, or a fusion protein and / or chimeric protein comprising a functional fragment of a TCR or functional fragments of one or more TCRs. A "native TCR" refers to a wildtype TCR that can be isolated from nature.
[0240] Each TCR variable domain comprises three "TCR complementarity determining regions (CDRs)" embedded in a framework sequence, one being the hypervariable region named CDR3. In the context of the present invention, CDRal, CDRa2 and CDRa3 denote a-chain CDRs, and CDRbl, CDRb2 and CDRb3 denote p-chain CDRs. The sequences encoding CDRal and CDRa2 are comprised in TRAV, the sequences encoding CDRa3 are comprised in TRAV and TRAJ, the sequences encoding CDRbl and CDRb2 are comprised in TRBV, and the sequences encoding CDRb3 are comprised in TRBV, TRBD and TRBJ. In TCRs, the CDR1 and CDR3 amino acid residues make contact with the antigenic peptide, while the CDR2 amino acid residues mainly contact the HLA molecule (Stadinski et al., J Immunol. 2014 June 15; 192(12): 6071-6082; Cole et al., J Biol Chem. 2014 Jan 10;289(2):628-38). The antigen specificity of a TCR is thus defined by the CDR3 and CDR1 sequences. The CDR2 sequences are not required for the determination of antigen specificity, but may play a role in the overall affinity of a TCR towards a peptide:MHC complex.
[0241] In further most preferred embodiments, the therapeutic protein is a multispecific antigen binding protein, comprising the antigen binding site A specifically binding to a peptide that is in complex with an MHC protein, and an antigen binding site B, wherein the antigen binding site B is accessible for the anti-idiotypic antibody or the fragment(s) thereof binding to the antigen binding site B when the antigen binding site A is bound to the peptide in complex with the MHCprotein. In other words, the therapeutic protein is a multispecific antigen binding protein, comprising the antigen binding site A specifically binding to a peptide that is in complex with an MHC protein, and an antigen binding site B that can be bound by the anti-idiotypic antibody or the fragment(s) thereof binding to the antigen binding site B when the antigen binding site A is bound to the peptide in complex with the MHC protein. In further embodiments, the therapeutic protein is a multispecific antigen binding protein, wherein the therapeutic protein can be bound by the anti-idiotypicantibody or the fragment(s) thereof when the antigen binding site A is bound to the peptide in complex with the MHC protein. Thus, the therapeutic protein as used herein is characterized that the anti-idiotypic antibody or the fragment(s) thereof specifically bind(s) to the antigen binding site B or the therapeutic protein, when the antigen binding site A is bound to a peptide that is in complex with an MHC protein. Thus, the therapeutic protein is characterized that a simultaneous binding of the antigen binding site A bound to the peptide MHC complex and the anti-idiotypic antibody or the fragment(s) thereof binding to the therapeutic protein is allowed. In particular, the therapeutic protein is a bispecific antigen binding protein specifically binding to a peptide in complex with a MHC complex and specifically binding to a further antigen binding site B.
[0242] In particular further embodiments, the antigen-binding site A specifically binds to a MAGEA4 / 8 derived peptide bound to a major histocompatibility complex (MHC) protein or wherein the antigen-binding site A specifically binds to a PRAME derived peptide bound to an MHC. These exemplary peptides are known to be beneficial for therapy. However, the skilled person knows that further target peptides to be bound by antigen binding site A could be used in the methods provided herein.
[0243] The "PRAME (antigenic) peptide" comprises or consists of the amino acid sequence SLLQHLIGL (SEQ ID NO: 2) which corresponds to amino acids 425-433 of the full length PRAME protein as accessible under the Uniprot accession number P78395 (as available on January 11, 2019) as disclosed in WO2022 / 233956 Al. The PRAME derived peptide which comprises or consist of the amino acid sequence SLLQHLIGL (SEQ ID NO: 2) is also herein referred to as PRAME-004. The PRAME-004 peptide is a peptide epitope derived from a tumor-associated or tumor-specific protein and is presented on the cell surface by molecules of the major histocompatibility complex (MHC). More particularly, the PRAME-004 derived peptide is presented on the cell surface in complex with HLA-A*02.
[0244] The "MAGE-A4" and "MAGE-A8" proteins have a sequence identity of 72% as determined by a protein sequence alignment using the BLASTP 2.9.0 algorithm (Stephen F. et al. (1997) Nucleic Acids Res. 25:3389-3402) as disclosed in WO2021 / 023658 Al. Furthermore, "MAGE-A4" and "MAGE-A8" both comprise the MAG-003 peptide, i.e., KVLEHVVRV (SEQ ID NO: 1).In particular further embodiments, the subject suffers from a disease and / or disorder, in particularfrom cancerand / ora tumorous disease. In particularfurtherembodiments, the subject suffers from a cancer being positive for the peptide that is specifically bound by the antigen binding site A in as such that the therapeutic protein might have a therapeutic benefit in the subject.
[0245] It is disclosed in the appended examples that the methods provided herein can be used for exemplary therapeutic proteins specifically binding to PRAME-004 and MAG003. Accordingly, in particular embodiments the subject suffers from a PRAME-positive cancer and / or from a MAGEA4 / 8 positive cancer. In further embodiments, the cancer from which the subject suffer is selected from the group consisting of adrenocortical carcinoma, bladder cancer, in particular bladder carcinoma, brain tumor, in particular glioblastoma, primary brain cancer, or atypical meningioma, breast cancer, in particular triple-negative breast cancer or breast carcinoma, cervical carcinoma, in particular cervical squamous cell carcinoma or endocervical adenocarcinoma, cholangiocellular carcinoma, colorectal cancer, in particular colon cancer, endometrial cancer, in particular uterine carcinoma or uterine carcinosarcoma, epithelial cancer of the larynx, esophageal carcinoma, fallopian tube cancer, gallbladder cancer, gastro-intestinal cancer, germ cell tumor, head and neck cancer, in particular head and neck adenocarcinoma, or head and neck squamous cell carcinoma, hepatocellular carcinoma, leukemia, in particular acute myeloid leukemia or chronic lymphocytic leukemia, lung cancer, in particular small cell lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma, non-small cell lung squamous cell carcinoma (sqNSCLC), or large cell carcinoma of the lung, lymphoma, in particular extranodal T / NK-cell lymphoma, non-Hodgkin lymphoma, or H. pylori-induced MALT nonHodgkin lymphoma, malignant peripheral nerve sheath tumors, melanoma, in particular amelanotic melanoma, uveal melanoma, or cutaneous melanoma, mesothelioma, oral cavity carcinomas, oral squamous carcinoma, ovarian cancer, in particular epithelial ovarian cancer, serous ovarian cancer, ovarian carcinoma or ovarian carcinosarcoma, papillary thyroid carcinoma, primary peritoneal cancer, in particular restricted to serous, clear cell, and endometrioid subtypes, prostate cancer, renal cancer, in particular renal carcinoma, in particular renal clear cell carcinoma, renal papillary cell carcinoma, salivary duct carcinoma, sarcoma, in particular Ewing's sarcoma, fibrosarcoma, liposarcoma, osteosarcoma, or synovial sarcoma, testicular cancer, in particular testicular germ cell tumor, thymoma, urothelial carcinoma and uterine carcinoma. In particular, embodiments, the cancer is selected from the group consisting of (advanced and / or metastatic) cutaneous melanoma, uveal melanoma, gynecologic cancers such as endometrial carcinoma including uterine carcinosarcoma, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer restricted to serous, clear cell, and endometrioid subtypes, synovial sarcoma, and sqNSCLC. In further particular embodiments, the cancer is selected from the group consisting melanoma and ovarian cancer, preferably wherein the canceris selected from the group consisting of (metastatic) cutaneous melanoma, (metastatic) uveal melanoma, and (metastatic) ovarian cancer.
[0246] As used herein, the antigen binding site B is a further binding site of the therapeutic protein as indicated above that is different from the antigen binding site A. The antigen binding site B may specifically bind to a cell surface antigen of a human immune cells, preferably? cells or natural killer (NK) cells. The antigen binding site B may comprise one or more polypeptide chains. The antigen binding site B may be derived from a TCR, or may be a TCR or fragment(s) thereof, or may be derived from an antibody, or may be an antibody or fragment(s) thereof. The antigen binding site B is not particularly limited as long as it can be bound by the anti-idiotypic antibody. In particular embodiments, the antigen binding site B specifically binds to an antigen selected from the group consisting of CD2, CD3, in particular CD3y, CD36, and / or CD3E, CD4, CD5, CD7, CD8, CD10, CDllb, CDllc, CD14, CD16, CD18, CD22, CD25, CD28, CD32a, CD32b, CD33, CD41, CD41b, CD42a, CD42b, CD44, CD45RA, CD49, CD55, CD56, CD61, CD64, CD68, CD69, CD89, CD90, CD94, CD95, CD117, CD123, CD125, CD134, CD137, CD152, CD163, CD193, CD203c, CD235a, CD278, CD279, CD287, Ly-6.2C, Mell4, Nkp46, NKG2D, GITR, FceRI, TCRa / p, TCRy / 6, HLA-DR and 4-1 BB, or combinations thereof. In preferred embodiments, the antigen binding site B specifically binds to an a / |3 T cell receptor (TCR) / CD3 complex. The skilled person is aware of various antigen binding sites B specifically binding to the a / |3 T cell receptor (TCR) / CD3 complex, e.g. WO2022 / 233957 Al, Borst et al.; Human Immunology, 29, 175-188, 1990, Shearman et al., The Journal of Immunology; vol. 147,4366-4373, no: 12; 1991, or EP 0403156A1. In table 1 below, various exemplary antibodies, also referred to it as recruiters, are provided, e.g. the BMA recruiters. For example, BMhanced, BMAV36, or BMAV10 are recruiters that might be comprised in the therapeutic protein. In particular embodiments, the therapeutic protein comprises a variable domain VH comprising a CDRH1, a CDRH2 and a CDRH3, and a VL comprising a CDRL1, a CDRL2, and a CDRL3, wherein CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 form an antigen binding site B. The skilled person thus knows how to include therapeutic proteins comprising an antigen binding site B.
[0247] In particular embodiments, the antigen binding site B of the therapeutic protein comprises a VH and a VL, wherein the antigen binding sites B specifically binding to the a / |3 T cell receptor (TCR) / CD3 complex,
[0248] wherein the VH comprises
[0249] (a) a CDRH1 comprising the amino acid sequence of SEQ ID NO: 3;
[0250] (b) a CDRH2 comprising the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 5, and
[0251] (c) a CDRH3 comprising the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 7, and
[0252] wherein the VL comprises(a) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 8,
[0253] (b) a CDRL2 comprising the amino acid sequence of SEQ ID NO: 9, and
[0254] (c) a CDRL3 comprising the amino acid sequence of SEQ ID NO: 10;
[0255] and optionally wherein each of the CDRH1, the CDRH2 and the CDRH3,
[0256] and / orthe CDRL1, CDRL2, and CDRL3 comprises upto three amino acid substitutions. Preferably, the antigen binding site B of the therapeutic protein comprises the VH comprising
[0257] (a) a CDRH1 comprising the amino acid sequence of SEQ ID NO: 3;
[0258] (b) a CDRH2 comprising the amino acid sequence of SEQ ID NO: 4, and
[0259] (c) a CDRH3 comprising the amino acid sequence of SEQ ID NO: 6, and
[0260] wherein the VL comprises
[0261] (a) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 8,
[0262] (b) a CDRL2 comprising the amino acid sequence of SEQ ID NO: 9, and
[0263] (c) a CDRL3 comprising the amino acid sequence of SEQ ID NO: 10;
[0264] and optionally wherein each of the CDRH1, the CDRH2 and the CDRH3,
[0265] and / orthe CDRL1, CDRL2, and CDRL3 comprises upto three amino acid substitutions. Preferably, the anti-idiotypic antibody or the fragment(s) thereof specifically bind(s) to the antigen binding site B comprising the CDRs of the antibody BMhanced as indicated in table 1, e.g. comprising SEQ ID Nos: 3, 4, 6, and 8, 9, and 10.
[0266] In further embodiments of the antigen binding site B, the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 11, 12, 13 and 14, or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NOs: 11, 12, 13 or 14 and preferably comprising the CDRH1, CDRH2, and CDRH3 as mentioned above in this respect; and wherein the VL comprises an amino acid sequence of SEQ ID NO: 15 or SEQ ID NO: 16, or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 15, and preferably comprising the CDRL1, CDRL2, and CDRL3 as mentioned above in this respect; and optionally wherein each of said CDRH1, CDRH2 and CDRH3, and / or said CDRL1, CDRL2 and CDRL3 comprises up to three amino acid substitutions.
[0267] In further preferred embodiments of the antigen binding site B, the antigen binding site B comprises
[0268] (i) a VH that comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 11, 12, 13 and 14, or (an) antigen binding fragment(s) thereof, and (ii) a VL that comprises an amino acid sequence of SEQ ID NO: 15 or 16, or (an) antigen binding fragment(s) thereof,optionally wherein the VH or the VL may comprise a further modification, e.g. a modification of the N-terminal and / or C-terminal amino acid(s), preferably wherein the N-terminal glutamine is substituted by a pyro-glutamate.
[0269] The antigen binding site A specifically binds to the peptide MHC complex as indicated above. The antigen binding site A comprises one or more polypeptide chains. The antigen binding site A may be derived from a TCR, or may be a TCR or fragment(s) thereof, or may be derived from an antibody, or may be an antibody orfragment(s) thereof. In the context of the present invention, the CDR / FR sequences in an a-, |3-, y- or 6-chain variable domain of the TCR is determined based on IMGT definition (Lefranc et al., Dev. Comp. Immunol., 2003, 27(l):55-77; www.imgt.org). Accordingly, CDR / FR amino acid positions when related to TCR or TCR-derived domains are indicated according to said IMGT definition. Preferably, the IMGT position of the CDR / FR amino acid positions of the variable domain Va is given in analogy to the IMGT numbering of TRAV5*01 and / or the IMGT position of the CDR / FR amino acid positions of the variable domain V|3 is given in analogy to the IMGT numbering of TRBV29-l*01. The skilled person knows antigen binding sites specifically binding to peptide-MHC complexes, e.g. WO2021023658 Al, WO2022 / 233956 Al. The antigen binding site A is not particularly limited as long as it can bind to the peptide-MHC complex. Exemplary antigen binding sites A are provided in the following that may be particularly be used in the herein provided invention. In particular embodiments, the antigen binding site A specifically binds to the peptide of SEQ ID NO: 1 (MAG-003 peptide) that is in complex with an MHC protein and comprises:
[0270] a T cell receptor (TCR) alpha variable domain (Va) and a TCR beta variable domain (V|3), wherein the Va domain comprises
[0271] (i) a CDRal comprising the amino acid sequence according to SEQ ID NO: 17,
[0272] (ii) a CDRa2 comprising the amino acid sequence according to SEQ ID NO: 18, and (iii) a CDRa3 comprising the amino acid sequence according to SEQ ID NO: 19; and wherein the V|3 domain comprises
[0273] (i) a CDRpi comprising the amino acid sequence according to SEQ ID NO: 20,
[0274] (ii) a CDR|32 comprising the amino acid sequence according to SEQ ID NO: 21, and (iii) a CDR|33 comprising the amino acid sequence according to SEQ ID NO: 22; wherein one or more of CDRal, CDRa2, CDRa3, CDR|31, CDR|32 and CDR|33 may comprise one, two or three amino acid mutations, wherein the mutation may be a deletion, an insertion, or a substitution, preferably a conservative substitution.
[0275] In further particular embodiments, the antigen binding site A comprises:
[0276] a Va comprising or consisting of the amino acid sequence according to SEQ ID NO: 23 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 23 and comprising the CDRal, CDRa2, and CDRa3 according to SEQ ID NOs: 17, 18, and 19, respectively; anda VP comprising or consisting of the amino acid sequence according to SEQ ID NO: 24 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 24 and comprising the CDR|31, CDR|32, and CDR|33 according to SEQ ID NOs: 20, 21, and 23, respectively.
[0277] In further particular embodiments, the antigen binding site A specifically binds to the peptide of SEQ ID NO: 2 (PRAME004 peptide) that is in complex with an MHC protein and comprises: a T cell receptor (TCR) alpha variable domain (Va) and a TCR beta variable domain (VP), wherein the Va domain comprises
[0278] (i) a CDRal comprising the amino acid sequence according to SEQ ID NO: 27,
[0279] (ii) a CDRa2 comprising the amino acid sequence according to SEQ ID NO: 28, and (iii) a CDRa3 comprising the amino acid sequence according to SEQ ID NO: 29; and wherein the VP domain comprises
[0280] (i) a CDRpi comprising the amino acid sequence according to SEQ ID NO: 30,
[0281] (ii) a CDRP2 comprising the amino acid sequence according to SEQ ID NO: 31, and (iii) a CDRP3 comprising the amino acid sequence according to SEQ ID NO: 32, wherein one or more of CDRal, CDRa2, CDRa3, CDRpi, CDRP2 and CDRP3 may comprise one, two or three amino acid mutations, wherein the mutation may be a deletion, an insertion, or a substitution, preferably a conservative substitution
[0282] In further particular embodiments, the antigen binding site A comprises:
[0283] a Va comprising or consisting of the amino acid sequence according to SEQ ID NO: 33 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 33 and comprising the CDRal, CDRa2, and CDRa3 according to SEQ ID NOs: 27, 28, and 29, respectively; and
[0284] a VP comprising or consisting of the amino acid sequence according to SEQ ID NO: 34 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 34 and comprising the CDRpi, CDRP2, and CDRP3 according to SEQ ID NOs: 30, 31, and 32, respectively.
[0285] The therapeutic protein is an antigen binding protein and comprises one or more polypeptide chains. As used herein, the term antigen binding protein includes antigen binding proteins of multiple different formats, including soluble antigen binding proteins, monovalent, bivalent and multivalent antigen binding proteins, monospecific, bispecific and multispecific antigen binding proteins, single chain antigen binding proteins and antigen binding proteins comprising two or more chains, fusion proteins and chimeric proteins. The skilled person is aware that the CDRs provided herein can be included in various formats as disclosed in the prior art, e.g., in BrinkmannU, Kontermann RE. The making of bispecific antibodies (MAbs. 2017 Feb / Mar;9(2):182-212, doi: 10.1080 / 19420862.2016.1268307) or WO 2019 / 012138. Table 1 below provides further sequences in the context of the therapeutic proteins that may be comprised in the therapeutic proteins.
[0286] The appended examples show that the method can be used for TCER molecules that are mulitspecific antigen binding proteins. The skilled person is aware that multispecific antigen binding proteins can also be generated in other formats. For example, the therapeutic protein may take the form of a TCR, an antibody, including engineered TCRs and antibodies, such as single chain fragment variable (scFv), disulfide-stabilized Fv (dsFv), scTVs, Fab, Fab', F(ab')2, nanobody, DARPin, Knottin, diabody, single-chain diabody or oligomers thereof. The "TCER®" is a soluble antigen binding protein comprising two antigen binding domains, a first variable domain (VA) and second variable domain (VB) and a further antigen binding domain that is formed by the heavy and light chain variable domains of an antibody, also referred to as "recruiter", such as variable heavy (VH) and variable light (VL) domains directed against a T cell antigen (such as CD3) or directed against TCRa / p or a combination thereof.
[0287] In particular embodiments, the therapeutic protein comprises or consists of a first polypeptide and a second polypeptide, wherein the first polypeptide and the second polypeptide of the therapeutic protein are covalently or non-covalently linked together. For example, the binding sites A and B may be in the format of an scFv, or the therapeutic protein may comprise a single chain TCR (scTCR) and / or a single-chain bispecific antibody. The therapeutic protein may also have the following structure, wherein a first polypeptide chain comprises a structure represented by formula:
[0288] V1-L1-V2 [I]
[0289] wherein VI is a first variable domain; V2 is a second variable domain; LI is a linker domain;
[0290] and wherein a second polypeptide chain comprises a structure represented by formula:
[0291] V3-L3-V4 [II]
[0292] wherein V3 is a third variable domain; V4 is a fourth variable domain; L3 is a linker; optionally wherein:
[0293] VI and V2 form the antigen binding site A and V3 and V4 form the antigen binding site B, or
[0294] VI and V2 form the antigen binding site B and V3 and V4 form the antigen binding site A, orVI and V3 form the antigen binding site A and V2 and V4 form the antigen binding site B, or
[0295] VI and V3 form the antigen binding site B and V2 and V4 form the antigen binding site A, or
[0296] VI and V4 form the antigen binding site A and V2 and V3 form the antigen binding site B, or
[0297] VI and V4 form the antigen binding site B and V2 and V3 form the antigen binding site A, and
[0298] optionally, wherein the first polypeptide and the second polypeptide are covalently or non-covalently linked together.
[0299] Ina further particular embodiment, the first polypeptide chain comprises a structure represented by formula:
[0300] V1-L1-V2-L2-C1 [III]
[0301] wherein VI is a first variable domain; V2 is a second variable domain; LI and L2 are linkers; L2 may be present or absent; Cl is a constant domain or a dimerizing portion thereofand present or absent, preferably wherein ClisCLa light chain constant domain or a dimerizing portion thereof;
[0302] and wherein a second polypeptide chain comprises a structure represented by formula:
[0303] V3-L3-V4-L4-C2 [IV]
[0304] wherein V3 is a third variable domain; V4 is a fourth variable domain; L3 and L4 are linkers; L4 may be present or absent; C2 is a constant domain or a dimerizing portion thereof and is present or absent, preferably wherein C2 is CH a heavy chain constant domain or a dimerizing portion thereof; and wherein preferably
[0305] VI and V2 form the antigen binding site A and V3 and V4 form the antigen binding site B, or
[0306] VI and V2 form the antigen binding site B and V3 and V4 form the antigen binding site A, or
[0307] VI and V3 form the antigen binding site A and V2 and V4 form the antigen binding site B, or
[0308] VI and V3 form the antigen binding site B and V2 and V4 form the antigen binding site A, or
[0309] VI and V4 form the antigen binding site A and V2 and V3 form the antigen binding site B, orVI and V4 form the antigen binding site B and V2 and V3 form the antigen binding site A, and
[0310] optionally, wherein the first polypeptide and the second polypeptide are covalently or non-covalently linked together.
[0311] In a further particular embodiment, the first polypeptide chain has a structure represented by the formula [V]:
[0312] V1-L1-V2-L2-C1-L5-FC1 [V]
[0313] and the second polypeptide chain has a structure represented by the formula [VI]:
[0314] V3-L3-V4-L4-C2-L6-FC2 [VI]
[0315] wherein VI to V4, LI to L4, Cl and C2 are as defined herein and wherein L5 and L6 are linkers and present or absent and FC1, and FC2 are Fc-domains and wherein FC1 and FC2 are the same or different.
[0316] The skilled person is well of aware of such a structure, e.g. W02019 / 012138 Al. The FC1 and / or FC2 may comprise or consist of the amino acid sequence SEQ ID NO: 37 and / or SEQ ID NO: 38; and / or LI and L3 comprise or consist of the amino acid sequence SEQ ID NO: 39. The TCER molecule also comprises such a structure. Exemplary, therapeutic proteins are provided in the following:
[0317] A therapeutic protein may comprise or consist of
[0318] a first polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 25 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 25 and comprising the CDRL1, CDRL2, CDRL3, CDR|31, CDR|32, and CDR|33 according to SEQ ID NOs: 8, 9, 10, 20, 21, and 22, respectively; and a second polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 26 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 26 and comprising the CDRal, CDRa2, CDRa3, CDRH1, CDRH2, and CDRH3 according to SEQ ID NOs: 17, 18, 19, 3, 5, and 6, respectively.
[0319] Alternatively, the therapeutic protein may comprise or consist of
[0320] a first polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 25, and
[0321] a second polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 26.
[0322] In a further particular embodiment, the therapeutic protein may comprise or consist ofa first polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 35 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 35 and comprising the CDRL1, CDRL2, CDRL3, CDR|31, CDR|32, and CDR|33 according to SEQ ID NOs: 8, 9, 10, 30, 31, and 32, respectively; and a second polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 36 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 36 and comprising the CDRal, CDRa2, CDRa3, CDRH1, CDRH2, and CDRH3 according to SEQ ID NOs: 27, 28, 29, 3, 4, and 6, respectively.
[0323] Alternatively, the therapeutic protein may comprise or consist of a first polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 35, and a second polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 36.
[0324] The therapeutic proteins may also be modified as long as the specificities of the protein is maintained and thus it may comprises a modification of the N-terminal and / or C-terminal amino acid(s), preferably wherein the N-terminal glutamine is substituted by a pyro-glutamate.
[0325] In a further aspect of the invention, the invention relates to anti-idiotypic antibodies binding to the therapeutic protein. As used herein the anti-idiotypic antibody or the fragment(s) thereof can be any antigen binding protein that specifically bind to the therapeutic protein and that additionally allow the binding of the therapeutic protein to the peptide-MHC complex. In general, the idiotope is the unique set of antigenic determinants (epitopes) of the variable portion of an antibody. In some cases it can be the actual antigen-binding site, and in some cases it may comprise variable region sequences outside of the antigen-binding site on the antibody itself. In particular embodiments, the anti-idiotypic antibody or the fragment(s) specifically bind to the antigen binding site B or to the antigen binding site A of the therapeutic protein. The anti-idiotypic antibody refers particularly to an antibody, which specifically binds to a binding specificity (e.g. an antigen binding site) such as a binding site of a therapeutic protein comprising immunoglobulin molecules, i.e. which is directed e.g. against an antigen binding site. In one embodiment, the anti-idiotypic antibody specifically binds to one or more of the variable domains of the antigen binding sites comprised in the therapeutic protein. In one embodiment the therapeutic protein is a multispecific antigen binding protein as indicated above. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that specifically binds an antigen. The term also covers any polypeptide or protein having a binding domain which is, or is homologous to, an antibody binding domain. Examples of antibodies are the immunoglobulin isotypes (e.g., IgG, IgE, IgM, IgD and IgA) and their isotypic subclasses; fragments which comprise an antigen binding domain such as Fab, scFv, Fv, dAb, Fd; anddiabodies. Antibodies may be polyclonal or monoclonal. A monoclonal antibody may be referred to herein as "mab". As antibodies can be modified in a number of ways, the term "antibody" should be construed as covering antibody fragments, derivatives, functional equivalents and homologues of antibodies, humanised antibodies, including any polypeptide comprising an immunoglobulin binding domain, whether natural or wholly or partially synthetic. Chimeric molecules comprising an immunoglobulin binding domain, or equivalent, fused to another polypeptide are therefore included. As used herein, the "fragment" refers to a functional fragment that typically refers to a portion of an antibody (or an antibody derived protein) or of a TCR that retains a specific biological or functional activity, such as antigen binding, even if it does not include the full native structure. For example, the fragment retains the ability to bind to a specific antigen or epitope.
[0326] In the following, exemplary anti-idiotypic antibodies and fragment(s) thereof are provided, which specifically bind to exemplary therapeutic proteins.
[0327] In one embodiment, the anti-idiotypic antibody or fragment(s) thereof comprises,
[0328] a VH comprising
[0329] (a) a CDRH1 comprising the amino acid sequence of SEQ ID NO: 40,
[0330] (b) a CDRH2 comprising the amino acid sequence of SEQ ID NO: 41,
[0331] (c) a CDRH3 comprising the amino acid sequence of SEQ ID NO: 42, and
[0332] a VL comprising
[0333] (a) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 43,
[0334] (b) a CDRL2 comprising the amino acid sequence of SEQ ID NO: 44,
[0335] (c) a CDRL3 comprising the amino acid sequence of SEQ ID NO: 45,
[0336] and optionally wherein each of the CDRH1, the CDRH2 and the CDRH3, and the CDRL1, CDRL2, and CDRL3 comprises up to three amino acid substitutions. Such anti-idiotypic antibody or its fragment(s) thereof specifically binds to the antigen binding site B, wherein the antigen binding site B specifically binds to an a / |3 T cell receptor (TCR) / CD3 complex. The "complementary determining region" (CDR) in the context of the anti-idiotypic antibodies or in the exemplary antigen binding sites B are assigned according to Kabat numbering. Tables 1 and 2 provide further sequence information, such as exemplary framework domains (FRs), or constant domains (e.g. CL or CH), in the context of the anti-idiotypic antibodies. Such sequences may also be comprised in the anti-idiotypic antibodies or in the fragments thereof.
[0337] In general, the particular embodiments as herein provided above and below in relation to the antigen binding site B also apply herein in this aspect
[0338] In a further embodiment, the anti-idiotypic antibody or fragment(s) thereof comprises
[0339] a VL comprising or consisting of the amino acid sequence according to SEQ ID NO: 46 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ IDNO: 46 and comprising the CDRL1, CDRL2, and CDRL3 according to SEQ ID NOs: 43, 44, and 45, respectively; and
[0340] a VH comprising or consisting of the amino acid sequence according to SEQ ID NO: 47 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 47 and comprising the CDRH1, CDRH2, and CDRH3 according to SEQ ID NOs: 40, 41, and 42, respectively.
[0341] In a further embodiment, the anti-idiotypic antibody or fragment(s) thereof comprises,
[0342] a first polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 48 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 48 and comprising the CDRL1, CDRL2, and CDRL3 according to SEQ ID NOs: 43, 44, and 45, respectively; and
[0343] a second polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 49 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 49and comprising the CDRH1, CDRH2, and CDRH3 according to SEQ ID NOs: 40, 41, and 42, respectively.
[0344] As indicated above, the anti-idiotypic antibody or the fragment(s) thereof specifically bind(s) to the antigen binding site B, wherein the antigen binding site B comprises a VH comprising (a) a CDRH1 comprising the amino acid sequence of SEQ ID NO: 3;
[0345] (b) a CDRH2 comprising the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 5, and
[0346] (c) a CDRH3 comprising the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 7, and
[0347] and a VL comprises
[0348] (a) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 8,
[0349] (b) a CDRL2 comprising the amino acid sequence of SEQ ID NO: 9, and
[0350] (c) a CDRL3 comprising the amino acid sequence of SEQ ID NO: 10;
[0351] and optionally wherein each of the CDRH1, the CDRH2 and the CDRH3,
[0352] and / or the CDRL1, CDRL2, and CDRL3 comprises up to three amino acid substitutions. Preferably, the anti-idiotypic antibody or the fragment(s) thereof specifically bind(s) to the antigen binding site B comprising the CDRs of the antibody BMhanced as indicated in table 1, e.g. comprising SEQ ID Nos: 3, 4, 6, and 8, 9, and 10.
[0353] In a further particular embodiment, the anti-idiotypic antibody or the fragment(s) thereof specifically bind(s) to the antigen binding site B, wherein the antigen binding site B comprises (iii) the VH comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 11, 12, 13 and 14, or an amino acid sequence having at least 85%, 90%,95%, 98% or 99% identity to SEQ ID NOs: 11, 12, 13 or 14 and preferably comprising the CDRH1, CDRH2, and CDRH3 as defined herein; and
[0354] (iv) the VL comprising an amino acid sequence of SEQ ID NO: 15 or SEQ ID NO: 16, or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 15, and preferably comprising the CDRL1, CDRL2, and CDRL3 as defined herein;
[0355] and optionally wherein each of said CDRH1, CDRH2 and CDRH3, and said CDRL1, CDRL2 and CDRL3 comprises up to three amino acid substitutions. In such embodiments, the anti-idiotypic antibody or the fragment(s) thereof bind(s) to an antibody or the fragment(s) thereof (e.g. the antigen binding site B) that specifically binds to a cell surface antigen of a human immune cells, preferably T cells or natural killer (NK) cells, preferably to an a / |3 T cell receptor (TCR) / CD3 complex. Such anti-idiotypic antibodies and the fragments thereof as provided herein above may be used in step b) of the methods of the first aspect.
[0356] In a further embodiment, anti-idiotypic antibodies or fragments thereof comprise,
[0357] a VH comprising
[0358] (a) a CDRH1 comprising the amino acid sequence of SEQ ID NO: 50,
[0359] (b) a CDRH2 comprising the amino acid sequence of SEQ ID NO: 51,
[0360] (c) a CDRH3 comprising the amino acid sequence of SEQ ID NO: 52, and
[0361] a VL comprising
[0362] (a) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 53,
[0363] (b) a CDRL2 comprising the amino acid sequence of SEQ ID NO: 54,
[0364] (c) a CDRL3 comprising the amino acid sequence of SEQ ID NO: 55;
[0365] or
[0366] a VH comprising
[0367] (a) a CDRH1 comprising the amino acid sequence of SEQ ID NO: 56,
[0368] (b) a CDRH2 comprising the amino acid sequence of SEQ ID NO: 57,
[0369] (c) a CDRH3 comprising the amino acid sequence of SEQ ID NO: 58, and
[0370] a VL comprising
[0371] (a) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 59,
[0372] (b) a CDRL2 comprising the amino acid sequence of SEQ ID NO: 60,
[0373] (c) a CDRL3 comprising the amino acid sequence of SEQ ID NO: 61;
[0374] and optionally wherein each of the CDRH1, the CDRH2 and the CDRH3, and the CDRL1, CDRL2, and CDRL3 comprises up to three amino acid substitutions. Such anti-typic antibodies specifically bind to an antigen binding site that specifically binds to the MAG003 peptide-MHC complex.
[0375] In particular further embodiments, the anti-idiotypic antibody or fragment(s) thereof comprise,a VL comprising or consisting of the amino acid sequence according to SEQ ID NO: 62 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 62 and comprising the CDRL1, CDRL2, and CDRL3 according to SEQ ID NOs: 53, 54, and 55, respectively; and
[0376] a VH comprising or consisting of the amino acid sequence according to SEQ ID NO: 63 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 63 and comprising the CDRH1, CDRH2, and CDRH3 according to SEQ ID NOs: 50, 51, and 52, respectively; or
[0377] a VL comprising or consisting of the amino acid sequence according to SEQ ID NO: 64 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 64 and comprising the CDRL1, CDRL2, and CDRL3 according to SEQ ID NOs: 59, 60, and 61, respectively; and
[0378] a VH comprising or consisting of the amino acid sequence according to SEQ ID NO: 65 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 65 and comprising the CDRH1, CDRH2, and CDRH3 according to SEQ ID NOs: 56, 57, and 58, respectively.
[0379] As indicated above, such anti-idiotypic antibodies or fragment(s) thereof bind to the antigen binding site A, which comprises particularly a TCR or fragment(s) thereof that binds to a peptide that is in complex with a major histocompatibility complex (MHC) protein. For example, such anti-idiotypic antibodies or fragment(s) may bind to the antigen binding site A, wherein the antigen binding site A specifically binds to the peptide SEQ ID NO: 1 that is in complex with an MHC protein. In general, the particular embodiments as herein provided above and below in relation to the antigen binding site A also apply herein in this aspect.
[0380] In further particular embodiments, the anti-idiotypic antibodies or fragment(s) thereof may specifically bind to the antigen binding site A, wherein the antigen binding site A comprises a T cell receptor (TCR) alpha variable domain (Va) and a TCR beta variable domain (VP), wherein the Va domain comprises
[0381] (i) a CDRal comprising the amino acid sequence according to SEQ ID NO: 17,
[0382] (ii) a CDRa2 comprising the amino acid sequence according to SEQ ID NO: 18, and (iii) a CDRa3 comprising the amino acid sequence according to SEQ ID NO: 19; and wherein the V|3 domain comprises
[0383] (i) a CDRpi comprising the amino acid sequence according to SEQ ID NO: 20,
[0384] (ii) a CDR|32 comprising the amino acid sequence according to SEQ ID NO: 21, and (iii) a CDR|33 comprising the amino acid sequence according to SEQ ID NO: 22; wherein one or more of CDRal, CDRa2, CDRa3, CDR|31, CDR|32 and CDR|33 may comprise one, two or three amino acid mutations, wherein the mutation may be a deletion, an insertion, or a substitution, preferably a conservative substitution.In further particular embodiments, the anti-idiotypic antibodies or fragment(s) thereof may specifically bind to the antigen binding site A, wherein the antigen binding site A comprises a Va comprising or consisting of the amino acid sequence according to SEQ ID NO: 23 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 23 and comprising the CDRal, CDRa2, and CDRa3 according to SEQ ID NOs: 17, 18, and 19, respectively; and
[0385] a VP comprising or consisting of the amino acid sequence according to SEQ ID NO: 24 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 24 and comprising the CDR|31, CDR|32, and CDR|33 according to SEQ ID NOs: 20, 21, and 23, respectively.
[0386] In further particular embodiments, the anti-idiotypic antibodies or fragment(s) thereof may specifically bind to the antigen binding site A, wherein the therapeutic protein comprising or consisting of
[0387] a first polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 25 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 25 and comprising the CDRL1, CDRL2, CDRL3, CDR|31, CDR|32, and CDR|33 according to SEQ ID NOs: 8, 9, 10, 20, 21, and 22, respectively; and a second polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 26 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 26 and comprising the CDRal, CDRa2, CDRa3, CDRH1, CDRH2, and CDRH3 according to SEQ ID NOs: 17, 18, 19, 3, 5, and 6, respectively. The therapeutic protein may further comprises a modification of the N-terminal and / or C- terminal amino acid(s), preferably wherein the N-terminal glutamine is substituted by a pyro-glutamate.
[0388] In further particular embodiments, the anti-idiotypic antibodies or fragment(s) thereof may specifically bind to
[0389] a first polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 35 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 35 and comprising the CDRL1, CDRL2, CDRL3, CDR|31, CDR|32, and CDR|33 according to SEQ ID NOs: 8, 9, 10, 30, 31, and 32, respectively; and a second polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 36 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 36 and comprising the CDRal, CDRa2, CDRa3, CDRH1, CDRH2, and CDRH3 according to SEQ ID NOs: 27, 28, 29, 3, 4, and 6, respectively; or to a first polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 25 or an amino acid sequence having at least 85%, 90%, 95%,98% or 99% identity to SEQ ID NO: 25 and comprising the CDRL1, CDRL2, CDRL3, CDR 1, CDR 2, and CDR 3 according to SEQ ID NOs: 8, 9, 10, 20, 21, and 22, respectively; and a second polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 26 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 26 and comprising the CDRal, CDRa2, CDRa3, CDRH1, CDRH2, and CDRH3 according to SEQ ID NOs: 17, 18, 19, 3, 5, and 6, respectively.
[0390] The herein provided and disclosed anti-idiotypic antibodies or the fragments thereof may comprise (a) labeling reagent(s). In such embodiments, the labeling reagent may be a labeling reagent selected from the group consisting of chemiluminescent or non-chemiluminescent labels, preferably, N-hydroxysuccinimide (NHS) ester, more preferably a SULFO-tag, fluorescent dyes, such as FITC, Alexa Fluor dyes, and Cy dyes, enzymatic labels, such as, horseradish peroxidase (HRP) and alkaline phosphatase (AP), biotin, and radioactive isotopes. In preferred aspects, the labeling reagent is a SULFO-tag.
[0391] The skilled person is aware of a SULFO-tag that can be used e.g. for MSD. For example, a SULFO-TAG is an NHS-Ester that is an N-hydroxysuccinimide ester, which readily couples to primary amine groups of proteins. SULFO-TAG conjugated proteins are used as detection reagents in MSD immunoassays. Sulfo-TAG NHS ester (disodium) is an N-hydroxysuccinimide ester that can be coupled to proteins via primary amine groups. Sulfo-TAG NHS ester (disodium) can be used for antibody labeling (e.g. CAS No. : 482618-42-8). As described in the appended examples, the SULFO-TAG can be coupled with the anti-idiotypic antibodies.
[0392] A further aspect of the invention relates to a nucleic acid or nucleic acids encoding the herein provided and disclosed anti-idiotypic antibodies or the fragments. A further aspect of the invention relates to a vector or vectors comprising such nucleic acid or nucleic acids. A further aspect of the invention relates a host cell comprising such nucleic acid or nucleic acids or such vector(s). The host cell may be a cell for recombinant expression, such as a Chinese Hamster Ovary (CHO) cell or a yeast cell.
[0393] A further aspect of the invention relates to a method of producing the herein provided and disclosed anti-idiotypic antibodies and the fragments thereof, wherein the method comprises culturing the host cell under suitable conditions, and optionally isolating the anti-idiotypic antibody produced by the host cells. A further embodiment relates to an anti-idiotypic antibody or the fragment(s) thereof as produced by the herein provided method.
[0394] A further aspect of the invention relates to a kit comprising the herein provided anti-idiotypic antibodies or its fragments thereof. The kit may be comprised in a packaging or a box. Optionally, further reagents for detecting, a solid phase coupled with the peptide MHC complex and / or a leaflet may be comprised in the kit.The herein provided and disclosed anti-idiotypic antibodies and the fragments thereof may be used in the herein provided methods, for example in determining a level of a protein comprising the antigen binding site A and / or the antigen binding site B. A further use may be in determining a level of anti-drug antibodies against a therapeutic protein in a sample.
[0395] A further aspect of the invention relates to a method for determining a level of a therapeutic protein in a sample, wherein the therapeutic protein comprises
[0396] (i) an antigen binding site A specifically binding to a peptide that is in complex with a major histocompatibility complex (MHC) protein, and
[0397] (ii) an antigen binding site B, and
[0398] wherein the method comprises
[0399] a) incubating the sample comprising the therapeutic protein with the anti-idiotypic antibody herein provided specifically binding to the antigen binding site B of the therapeutic protein; or with the anti-idiotypic antibody herein provided specifically binding to the antigen binding site A of the therapeutic protein, b) incubating the therapeutic protein bound to the anti-idiotypic antibody with the anti-idiotypic antibody specifically binding to the other antigen binding site of the therapeutic protein that was not bound by the anti-idiotypic antibody in step a), and
[0400] c) detecting the anti-idiotypic antibody bound to the therapeutic protein and thereby determining the level of the therapeutic protein in the sample.
[0401] In such methods, the method may comprise before step a) immobilizing of the capturing anti-idiotypic antibody (the anti-idiotypic antibody as used in step a)) on a solid phase. More preferably, the anti-idiotypic antibody or the fragment(s) thereof specifically binding to the antigen binding site A of the therapeutic protein may be immobilized on a solid phase.
[0402] In particular embodiments of such a method, the method comprises
[0403] a) incubating the sample comprising the therapeutic protein with the anti-idiotypic antibody herein provided specifically binding to the antigen binding site A of the therapeutic protein,
[0404] b) incubating the therapeutic protein bound to the anti-idiotypic antibody with the anti-idiotypic antibody herein provided specifically binding to the antigen binding site B of the therapeutic protein, and
[0405] c) detecting the anti-idiotypic antibody bound to the therapeutic protein in step b) and thereby determining the level of the therapeutic protein in the sample.In such embodiments, the anti-idiotypic antibody used in step a) is used to immobilize the therapeutic protein on a solid phase, and wherein the anti-idiotypic antibody used in step b) is used in detecting the therapeutic protein.
[0406] In a further aspect, the invention relates to a method for determining a level of anti-drug antibodies against a therapeutic protein in a sample,
[0407] wherein the therapeutic protein comprises
[0408] (i) an antigen binding site A specifically binding to a peptide that is in complex with a major histocompatibility complex (MHC) protein, and
[0409] (ii) an antigen binding site B, and
[0410] wherein the method comprises
[0411] a) incubating the sample with (al) the therapeutic protein comprising a capturing reagent and (a2) the therapeutic protein comprising a labeling reagent, and b) detecting the therapeutic protein comprising the labeling reagent that is bound to the anti-drug antibody, and thereby determining the level of the anti-drug antibodies in the sample, and wherein the anti-idiotypic antibody or the fragment(s) thereof as provided above is used.
[0412] In particular embodiments, the anti-idiotypic antibody or the fragment(s) thereof specifically binding to the antigen binding site B is(are) used as provided herein above. Preferably, the anti-idiotypic antibody or the fragment(s) thereof specifically binding to the antigen binding site B is(are) used as a positive control. The herein provided disclosure and definitions also apply to the method provided in this aspect. A capturing reagent may be used to immobilize / enrich the therapeutic protein on a solid phase, e.g. a biotin tag. In further embodiments, the incubated mix as provided in step a) is incubated with the solid phase and after incubation the non-bound fraction is washed away and subsequently step b) is conducted. Thus, in particular embodiments the method described may consists of the above described steps.
[0413] As used herein, the terms "comprising", "including", "having" or grammatical variants thereof are to be taken as specifying the stated features, integers, steps or components but do not preclude the addition of one or more additional features, integers, steps, components or groups thereof. The terms "comprising" / "including" / "having" encompass the terms "consisting of" and "consisting essentially of". Thus, wheneverthe terms "comprising" / "including" / "having" are used herein, they can be replaced by "consisting essentially of" or, preferably, by "consisting of". The terms "comprising" / "including" / "having" mean that any further component (or likewise features, integers, steps and the like) can be present.
[0414] The term "consisting of" means that no further component (or likewise features, integers, steps and the like) can be present.
[0415] As used herein the term "about" refers to ± 10%.As used herein, "a" or "an" may mean one or more. Importantly, when it is referred herein to an or the immune checkpoint inhibitor always also multiple immune checkpoint inhibitors are encompassed.
[0416] The definitions of the words or drawing elements described herein are meant to include not only the combination of elements which are literally set forth, but all equivalent structure, material or acts for performing substantially the same function in substantially the same way to obtain substantially the same result. In this sense, it is therefore contemplated that an equivalent substitution of two or more elements may be made for any one of the elements described and its various embodiments or that a single element may be substituted for two or more elements in a claim.
[0417] Changes from the claimed subject matter as viewed by a person with ordinary skill in the art, now known or later devised, are expressly contemplated as being equivalents within the scope intended and its various embodiments. Therefore, obvious substitutions now or later known to one with ordinary skill in the art are defined to be within the scope of the defined elements. This disclosure is thus meant to be understood to include what is specifically illustrated and described herein, what is conceptually equivalent, what can be obviously substituted, and also what incorporates the essential ideas.
[0418] Table 1 Exemplary amino acid sequences referred to herein
[0419] SEQ Description /
[0420] ID Region / Sequence
[0421] NO Domain
[0422] MAG-003
[0423] 1 KVLEHVVRV
[0424] peptide
[0425] PRAME-004
[0426] 2 SLLQHLIGL
[0427] peptide
[0428] BMhanced,
[0429] BMAV36,
[0430] 3 BMAV10 SYVMH
[0431] CDRH1
[0432] (Kabat)
[0433] BMhanced
[0434] 4 YINPRNDVTKYAEKFQG
[0435] CDRH2
[0436] BMAV36,
[0437] 5 BMAV10 YINPYNDVTKYAEKFQG
[0438] CDRH2
[0439] BMhanced,
[0440] 6 BMAV36 GSYYDYEGFVY
[0441]
[0442] CDRH3BMAV10
[0443] GSYYDYDGFVY CDRH3
[0444] BMhanced,
[0445] BMAV36,
[0446] SATSSVSYMH BMAV10
[0447] CDRL1
[0448] BMhanced,
[0449] BMAV36,
[0450] DTSKLAS BMAV10
[0451] CDRL2
[0452] BMhanced,
[0453] BMAV36,
[0454] QQWSSNPLT BMAV10
[0455] CDRL3
[0456] EVQLVQSGAEVKKPGASVKVSCKASGYKFTSYVMHWVRQAPGQGLEWM BMhanced GYINPRNDVTKYAEKFQGRVTLTSDTSTSTAYMELSSLRSEDTAVYYCARGSY VH YDYEGFVYWGQGTLVTVSSEPKSS EVQLVQSGAEVKKPGASVKVSCKASGYKFTSYVMHWVRQAPGQGLEWM BMA031-V36
[0457] GYINPYNDVTKYAEKFQGRVTLTSDTSTSTAYMELSSLRSEDTAVHYCARGSY VH YDYEGFVYWGQGTLVTVSS EVQLVQSGAEVKKPGASVKVSCKASGYKFTSYVMHWVRQAPGQGLEWM BMA031-V10
[0458] GYINPYNDVTKYAEKFQGRVTLTSDTSTSTAYMELSSLRSEDTAVHYCARGSY VH YDYDG FVYWGQGTLVTVSS EVQLVQSGAEVKKPGASVKVSCKASGYKFTSYVMHWVRQAPGQGLEWM BMA031 DOI GYINPRNDVTKYAEKFQGRVTLTSDTSTSTAYMELSSLRSEDTAVHYCARGSY VH YDYEGFVYWGQGTLVTVSS BMhanced,
[0459] QIQMTQSPSSLSASVGDRVTITCSATSSVSYMHWYQQKPGKAPKRWIYDTS BMAV36,
[0460] KLASGVPSRFSGSGSGTDYTLTISSLQPEDAATYYCQQWSSNPLTFGGGTKV BMAV10
[0461] EIK VL BMA V36 VL XIQMTQSPSSLSASVGDRVTITCSATSSVSYMHWYQQKPGKAPKRWIYDTS ("pyro KLASGVPSRFSGSGSGTDYTLTISSLQPEDAATYYCQQWSSNPLTFGGGTKV glutamate") EIK
[0462] X = pyro glutamate
[0463] MAG-003 DSSSTY
[0464] TCER CDRal
[0465] MAG-003 IYSSQDQ
[0466] TCERCDRa2
[0467] MAG-003 CAEMTSESKIIF
[0468] TCER CDRa3
[0469] MAG-003 PGHDY
[0470] TCERCDRP1
[0471] MAG-003 FCYGTP
[0472] TCER CDRP2
[0473] MAG-003 CASRADTGELFF
[0474]
[0475] TCER CDRP3MAG-003 E D VEQS LF LS VR EG DS VV 1 N CTYTDSSSTYLY WY KQE PG KG LQLLTYIYSSQD TCER TCR Va QKQDQRLTVLLNKKDKHLSLRIADTQTGDSAIYFCAEMTSESKIIFGSGTRLSI RP MAG-003 DAGVIQSPRHEVTEMGQEVTLRCKPIPGHDYLFWYRQTMMRGLELLFYFCY TCER TCR VP GTPCDDSGMPEDRFSAKMPNASFSTLKIQPSEPRDSAVYFCASRADTGELFF GEGSRLTVL MAG-003 XIQMTQSPSSLSASVGDRVTITCSATSSVSYMHWYQQKPGKAPKRWIYDTS TCER KLASGVPSRFSGSGSGTDYTLTISSLQPEDAATYYCQQWSSNPLTFGGGTKV
[0476] polypeptide EIKGGGSGGGGDAGVIQSPRHEVTEMGQEVTLRCKPIPGHDYLFWYRQTM 1 ("pyro MRGLELLFYFCYGTPCDDSGMPEDRFSAKMPNASFSTLKIQPSEPRDSAVYF glutamate or CASRADTGELFFGEGSRLTVLEPKSSDKTHTCPPCPAPPVAGPSVFLFPPKPK glutamine") DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLP PCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP
[0477] X = pyro glutamate or glutamine
[0478] MAG-003 E D VEQS LF LSVR EG DS VV 1 N CTYTDSSSTYLY WY KQE PG KG LQLLTYIYSSQD TCER QKQDQRLTVLLNKKDKHLSLRIADTQTGDSAIYFCAEMTSESKIIFGSGTRLSI
[0479] polypeptide RPGGGSGGGGEVQLVQSGAEVKKPGASVKVSCKASGYKFTSYVMHWVRQ 2 APGQGLEWMGYINPYNDVTKYAEKFQGRVTLTSDTSTSTAYMELSSLRSED TAVHYCARGSYYDYEGFVYWGQGTLVTVSSEPKSSDKTHTCPPCPAPPVAG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKG QPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKT TPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS P PRAME-004 VKEFQD
[0480] TCER CDRal
[0481] PRAME-004 FGPYGKE
[0482] TCER CDRa2
[0483] PRAME-004 ALYNNYDMR
[0484] TCER CDRa3
[0485] PRAME-004 SGHNS
[0486] TCER CDRP1
[0487] PRAME-004 FQNTAV
[0488] TCER CDRP2
[0489] PRAME-004 ASSPGATDKQY
[0490] TCER CDRP3
[0491] PRAME-004 ILNVEQSPQSLHVQEGDSTKFTCSFPVKEFQDLHWYRKETAKSPEFLFYFGPY TCER TCR Va GKEKKKGRISATLNTKEGYSYLYITDSQPEDSATYLCALYNNYDMRFGAGTRL TVKP PRAME-004 GVIQSPRHEVTEMGQEVTLRCKPISGHNSLFWYRETPMQGLELLIYFQNTAV TCER TCR VP IDDSGMPEDRFSAKMPNASFSTLKIQPSEPRDSAVYFCASSPGATDKQYFGP GTRLTVL PRAME-004 XIQMTQSPSSLSASVGDRVTITCSATSSVSYMHWYQQKPGKAPKRWIYDTS TCER KLASGVPSRFSGSGSGTDYTLTISSLQPEDAATYYCQQWSSNPLTFGGGTKV
[0492]
[0493] polypeptide EIKGGGSGGGGGVIQSPRHEVTEMGQEVTLRCKPISGHNSLFWYRETPMQ1 ("pyro GLELLIYFQNTAVIDDSGMPEDRFSAKMPNASFSTLKIQPSEPRDSAVYFCAS glutamate or SPGATDKQYFGPGTRLTVLEPKSSDKTHTCPPCPAPPVAGPSVFLFPPKPKDT glutamine") LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYR VVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPC RDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP
[0494] X = pyro glutamate or glutamine
[0495] PRAME-004 ILNVEQSPQSLHVQEGDSTKFTCSFPVKEFQDLHWYRKETAKSPEFLFYFGPY TCER GKEKKKGRISATLNTKEGYSYLYITDSQPEDSATYLCALYNNYDMRFGAGTRL
[0496] polypeptide TVKPG G G S G G G G EVQLVQSGAEVKKPGASVKVSCKASGYKFTSYVMHWV 2 RQAPGQGLEWMGYINPRNDVTKYAEKFQGRVTLTSDTSTSTAYMELSSLRS EDTAVYYCARGSYYDYEGFVYWGQGTLVTVSSEPKSSDKTHTCPPCPAPPVA GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAK GQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS LSP
[0497] Fc region 1 EPKSSDKTHTCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE DPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDWLNGKEY KCKVSNKALPASIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGF YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSP
[0498] Fc region 2 EPKSSDKTHTCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE DPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDWLNGKEY KCKVSNKALPASIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFY PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSP
[0499] linker GGGSGGGG
[0500] Anti-idiotypic DTYLH
[0501] antibody
[0502] against B
[0503] CDRH1
[0504] Anti-idiotypic KIDPTTGNSKYDPKFQG
[0505] antibody
[0506] against B
[0507] CDRH2
[0508] Anti-idiotypic GNDYWYFDV
[0509] antibody
[0510] against B
[0511] CDRH3
[0512] Anti-idiotypic RASESVDNYGISFMN
[0513] antibody
[0514] against B
[0515] CDRL1
[0516] Anti-idiotypic GAANQGT
[0517]
[0518] antibodyagainst B
[0519] CDRL2
[0520] Anti-idiotypic QQSKEVPWT
[0521] antibody
[0522] against B
[0523] CDRL3
[0524] Anti-idiotypic DIVLTQSPASLAVSLGQRATISCRASESVDNYGISFMNWFQQKPGQPPKLLIY antibody GAANQGTGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQSKEVPWTF against B GGGTKLEIK
[0525] VL
[0526] Anti-idiotypic EVQLQQSGAELVKPGTSVKLSCTVSGFNIKDTYLHWVKQRPEQGLEWIGKID antibody PTTGNSKYDPKFQGKATITSGTSPNTANLQLSSLTSEDTAVYYCAFGNDYWY against B FDVWGAGTTVTVSS
[0527] VH
[0528] Anti-idiotypic DIVLTQSPASLAVSLGQRATISCRASESVDNYGISFMNWFQQKPGQPPKLLIY antibody GAANQGTGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQSKEVPWTF against B GGGTKLEI KRADAAPTVSI FPPSSEQLTSGG ASVVCFLN N FYPKDI N VKWKI D Light chain GSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTS PIVKSFNRNEC
[0529] Anti-idiotypic EVQLQQSGAELVKPGTSVKLSCTVSGFNIKDTYLHWVKQRPEQGLEWIGKID antibody PTTGNSKYDPKFQGKATITSGTSPNTANLQLSSLTSEDTAVYYCAFGNDYWY against B FDVWGAGTTVTVSSAKTTPPSVYPLAPGSAAQ.TNSMVTLGCLVKGYFPEPV Heavy chain TVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPAS STKVDKKIVPRDCGCKPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCVVVDISK DDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKE FKCRVNSAAFPAPIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITD FFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNVQKSNWEAG NTFTCSVLHEGLHNHHTEKSLSHSPGK
[0530] Anti-idiotypic
[0531] antibody 1
[0532] RSWMN
[0533] against A
[0534] CDRH1
[0535] Anti-idiotypic
[0536] antibody 1
[0537] RIYPGDGDTRYNGKFKG
[0538] against A
[0539] CDRH2
[0540] Anti-idiotypic
[0541] antibody 1
[0542] EVYYDMDY
[0543] against A
[0544] CDRH3
[0545] Anti-idiotypic
[0546] antibody 1
[0547] RTSKNIYKYLA
[0548] against A
[0549] CDRL1
[0550] Anti-idiotypic
[0551] antibody 1 SGSTLQS
[0552]
[0553] against ACDRL2
[0554] Anti-idiotypic
[0555] antibody 1 QQHNEYPWT
[0556] 55
[0557] against A
[0558] CDRL3
[0559] Anti-idiotypic
[0560] antibody 2
[0561] 56 SSWMN
[0562] against A
[0563] CDRH1
[0564] Anti-idiotypic
[0565] antibody 2
[0566] 57 RIYPGDGDFKYNGKFKG
[0567] against A
[0568] CDRH2
[0569] Anti-idiotypic
[0570] antibody 2
[0571] 58 EGYYYDIGPWFAS
[0572] against A
[0573] CDRH3
[0574] Anti-idiotypic
[0575] antibody 2
[0576] 59 RASQSVSTSRYTYMH
[0577] against A
[0578] CDRL1
[0579] Anti-idiotypic
[0580] antibody 2
[0581] 60 FASNLES
[0582] against A
[0583] CDRL2
[0584] Anti-idiotypic
[0585] antibody 2
[0586] 61 QHIWEIPWT
[0587] against A
[0588] CDRL3
[0589] Anti-idiotypic
[0590] antibody 1 DVQITQSPSYLAASPGETITINCRTSKNIYKYLAWFQEKPGKTNKFLIYSGSTLQ 62
[0591] against A SGIPSRFSGSGSGTDFTLTISSLEPEDFAMYYCQQHNEYPWTFGGGTKLEIK VL
[0592] Anti-idiotypic QVQLQQSGPELVKPGASVKISCKASGYAFNRSWMNWVKQRPGQGLEWIG
[0593] antibody 1
[0594] 63 RIYPGDGDTRYNGKFKGKAKLTADISSSTAHMQLSSLTSEDSAVYFCAREVYY against A
[0595] DMDYWGQGTSVTVSS VH
[0596] Anti-idiotypic DIVLTQSPASLTVSLGQRATIACRASQSVSTSRYTYMHWYQQRPGQPPKLLI
[0597] antibody 2
[0598] 64 KFASNLESGVPARFSGSGSGTDFTLNIHPVEEEDSATYYCQHIWEIPWTFGG against A
[0599] GTKLEIT VL
[0600] Anti-idiotypic QVQLQQSGPELVRPGASVKISCKGSGYAFSSSWMNWVKQRPGQGLEWIG
[0601] antibody 2
[0602] 65 RIYPGDGDFKYNGKFKGKAILSADKSSSTAYMQLSSLTSVDSAVYFCAREGYY against A
[0603] YDIGPWFASWGQGTLVTVSA
[0604]
[0605] VH
[0606] The present invention is illustrated by the appended non-limiting Figures and Examples.Figure 1: TCERs structure. The structure and different domains of both TCERs used in the PK assay are depicted. TCER_NR (non-recognizing) is a negative control (NC) TCER that does not bind to the specific pHLA, the CD3-TCR complex on T cells and is not recognized by anti-idiotype Abs directed against MAG003 TCER.
[0607] Figure 2: MSD assay format and principle. Top: scheme of two assay formats used to detect MAG003 TCER with the MSD platform. Option 1 was also used switching the Abs (i.e., sulfo-tagged anti-TCR Ab as detection reagent and anti-recruiter Ab as capture reagent). Bottom: Depiction of the electrochemiluminescent reactions taking place during detection.
[0608] Figure 3: Antigens for anti-idiotype Ab generation and selection. The antigen for immunization was IMA-M07-mFc, a TCER molecule containing the variable domains of the MAG003 TCER fused to mouse lgG2a Fc domains. Screening for the anti-recruiter antibodies (anti-VH-VL) was done using the positive control TPP-79 containing the same VH and VL and constant domains CH2-CH3 as the MAG003 TCER, but different variable domains the TCR and the negative control TPP-93, a variant of the MAG003 TCER containing different VH and VL domains. Anti-TCER antibodies were screened with IMA-M11, which is another variant of the MAG003 TCER containing different VH and VL domains, as a positive control and the above-described TPP-79 as a negative control. Sequences of all antigens are provided below.
[0609] Figure 4: ELISA of 14C4B6B5. Plates were coated with either the positive control (a TCER molecule with the same VL and VH as for immunization, but with human constant domains and different variable domains of the TCR, see sequences below), or the negative control (a TCER molecule with the different VL and VH as for the positive control and also with human constant domains, see sequences below), or human IgG. These results indicate that only the variable domains of the recruiter are recognized by the antibody 14C4B6B5.
[0610] Figure 5: ELISA of anti-TCR antibodies. Plates were coated with either the positive control for anti-TCR antibodies (a TCER molecule with the same variable domains of the TCR but different VH and VL sequences, see sequences below), or the corresponding negative control (a TCER molecule with the same VL and VH as for the positive control, but different variable domains of the TCR, see sequences below), or human IgG. Both the antibody 5F2G7A5 and 14H7H4G12 superficially recognize the variable domains of the correct TCR.
[0611] Figure 6: Anti-idiotype antibodies recognizing MAG003 TCER. The dissociation constants (KD) of each Ab clone are shown, highlighting with asterisks the ones selected for testing in the ELISA sandwich format assays (P, C, B, H, A, S, T, see Table 2). Clones C and S were chosen for the MSD PK assay.Figure 7: Test of different capture and detection Ab combinations in a sandwich ELISA format detecting MAG003 TCER. Background subtracted absorbance (A) vs. TCER_WT cone. (ng / mL) in the presence of pooled HS from six HD (1:2 dilution) is depicted. The absorbance average of the blank samples (no TCER_WT) at indicated cone, of capture and detection clones were defined as the LODs and are indicated with color-coded dotted lines. Capture Ab: clone C or P; detection Ab: clone S orT. Experiment PK-009.
[0612] Figure 8: MSD PK assay using anti-idiotype antibodies (option 1 in Figure 2). ECL values vs. TCER_WT cone. (ng / mL) in the presence of HS from different HD (HS#1, 2 and 3) (1:16 dilution) are depicted. Capture Ab: clone S; detection Ab: clone C; TCER_WT : 500 ng / mL starting cone., DF: 5, 7 cone. Experiment PK-014.
[0613] Figure 9: MSD PK assay using pHLA as capture reagent (option 2 in Figure 2). ECL values vs. TCER_WT cone. (ng / mL) in the presence of pooled HS (HS#3 and HS#5) (1:2 and 1:4 dilutions) are depicted. Capture: pHLA monomer; detection Ab: clone S; TCER_WT cone.: 1000, 300 and 30 ng / mL. Experiment PK-020.
[0614] Figure 10: Dilutional Linearity. ECL values vs. TCER_WT cone. (ng / mL) in the presence of HS#8 (MRD, 1:4 dilution) were used to generate the curve. The white symbols indicate the excluded standards that did not meet the acceptance criteria or were outside the established linearity range. Color code indicates plate-specific standards (blue for high and red for low TCER_WT cone.). Capture: pHLA monomer, cone.: 0.66 pg / mL; detection Ab: clone S, cone.: 1 pg / mL; TCER_WT: 10 pg / mL starting cone., DF: 2, 19 cone. Experiment PK-022.
[0615] Figure 11: ADA assay bringing format scheme using an anti-recruiter Ab as PC. The TCER is tagged with biotin (capture reagent) or a sulfo-tag (detection reagent) for the MSD platform.
[0616] The Examples illustrate the invention.
[0617] Examples
[0618] Example 1
[0619] The results and conclusions are shown in the following obtained during the development of the clinical pharmacokinetics (PK) assay using the Meso Scale Discovery (MSD) platform for the detection and quantification of an anti-MAGE003 (or MAG-003) therapeutic protein in the format of a T cell engaging receptor (TCER) within the serum of treated patients. Furthermore, it is shown that the methods herein described also can be used for further peptide-MHC complexes and thedetection and quantification of a therapeutic protein specifically binding to PRAME-004 are provided.
[0620] Abbreviations
[0621] Abbreviation Complete name
[0622] 4PL Four parameter logistic
[0623] Ab Antibody
[0624] BSA Bovine serum albumin
[0625] Cone. Concentration / s
[0626] DF Dilution factor
[0627] ECL Electrochemiluminescence
[0628] ELISA Enzyme-linked immunosorbent assay
[0629] HD Healthy donors
[0630] HRP Horseradish peroxidase
[0631] HS Human serum
[0632] HS pool Pooled human serum from 10 healthy donors (unless specified differently)
[0633] LLOQ Lower limit of quantification
[0634] LOD Limit of detection
[0635] MRD Minimum required dilution
[0636] MSD Meso Scale Discovery
[0637] NC Negative control
[0638] NR Non-recognizing
[0639] ON Overnight
[0640] PBS Phosphate -buffered saline
[0641] pH LA Peptide-bound Human Leukocyte Antigen
[0642] PK Pharmacokinetics
[0643] RT Room temperature
[0644] SOP Standard operating procedure
[0645] TCER T cell engaging receptor
[0646] TCR T cell receptor
[0647] ULOQ Upper limit of quantification
[0648] Wl Working instruction
[0649]
[0650] Wo. Without
[0651] Assay principle
[0652] PK assay prior-art
[0653] Immune assays employing a sandwich layout had been used to quantify biologies in PK analyses. For example, the use of a sandwich ELISA for RiboMab02.1 quantification, employing a murine biotinylated anti-idiotype capture antibody (Ab) and an Alexa Fluor 647-conjugated rabbit antihuman K light chain detection Ab is described [1]. A similar layout was used during thedevelopment of the herein provided clinical PK assay set-up, using two anti-idiotype antibodies targeting different arms of the TCER. However, the inventors ultimately developed a new assay strategy that can be performed on the MSD (Meso Scale Discovery) platform and a different capture reagent.
[0654] Previously, an ELISA based assay in a pre-clinical setting had been used for quantification of MAG003 TCER molecules in the plasma of infused mice. To quantify MAG003 TCER molecules in the plasma samples, the target pHLA complex was used to capture this TCER and Protein L-HRP was used for detection via the VL domain of the Ab part.
[0655] Clinical PK assay using MSD platform
[0656] The following is a general description of the MSD PK assay procedure for MAG003 TCER: Streptavidin-coated MSD plates (Small Spot SA SECTOR) were blocked with 3% BSA (bovine serum albumin in PBS) for lhr at RT or overnight at 2-8°C. Following washing steps with Wash Buffer (0.05% Tween20 in PBS), MSD plates were incubated with biotinylated pHLA monomers for lhr at RT (previous versions incubated with biotinylated anti-idiotype Ab against either domain of the TCER). After further washing steps, the MSD plates were blocked again with 3% BSA for lhr at RT and washed. After applying the minimal required dilution (MRD), samples with TCER_WT were incubated for lhr at RT (during development TCER_NR, a non-recognizing negative control TCER was also used, Figure 1). Following the washing steps with Wash Buffer, the plates were incubated with SULFO-TAG conjugated anti-idiotype Ab (recognizing the recruiter domain of the bispecific in the final assay version) for 5 min at RT. After the next washing steps with Wash Buffer, Read Buffer B was added and the resulting electrochemiluminescence (ECL) signal was read within 5-10 minutes on the MSD reader (Plate Reader, MESO QuickPlex SQ120). The main analysis was performed using the MSD Discovery WorkBench software (version 4.0) and extra analyses were performed using MS Excel.
[0657] Figure 2 depicts the assay format and the ECL reaction. Although both options were tested, the selected and advantageous format was Option 2.
[0658] 1 Materials and Methods
[0659] 1.1 ELISA
[0660] 1.1.1 Materials
[0661] Material Provider Storage
[0662] PBS, lx, 500 ml Lonza, 14190-144 RT, 4°C
[0663] BSA Sigma Aldrich, A7030 4°C
[0664] Tween20 Sigma Aldrich, P1379 RT
[0665] TMB Sigma Aldrich, T0440 4°C, in the dark
[0666] H2SO4Acros Organics, RT
[0667]
[0668] A0236138MAG003_TCER_WT (TCER4: wild Immatics, lot: 4°C
[0669] type MAG003) 1075581004, material
[0670] Nr.: 5004333
[0671] TCER_NR (non-recognizing) (TCER2: Immatics 4°C
[0672] 100-NU(Varl7)-R16PlC10HiAff#l- dsFcKO-GK)
[0673] Human serum BiolVT -20°C
[0674] Anti-idiotype antibodies (10 anti- Genscript -20°C / 4°C
[0675] TCR clones and 12 anti-recruiter
[0676] clones)
[0677] HRP Conjugation Kit- Lightning-Link Abeam, abl02890 -20°C
[0678] Zeba™ spin Desalting columns, 0.5 Thermo Fisher 4°C
[0679] ml Scientific,
[0680] Goat anti-Mouse IgG Fc Secondary Thermo Fisher 4°C
[0681] Ab, HRP, Img Scientific, SA5-10276
[0682] Goat anti-Mouse IgG (H+L) crossThermo Fisher -20°C
[0683] adsorbed Secondary Ab, HRP, Img Scientific, G-21040
[0684] Goat anti-Mouse IgG (H+L) crossJackson -70°C
[0685] adsorbed Secondary Ab, HRP, Img ImmunoResearch, 115- 035-071
[0686] Goat anti-Mouse IgG Fc (HRP) Abeam, ab97265 4°C
[0687] IgG, human Biomol, I1903-90S1-250 -20°C
[0688] Sealing film ROTILABO® for Carl Roth, H769.1 RT
[0689] multiwell-plates, Polyester, Non- sterile, 25 pm
[0690] Nunc-lmmuno® MicroWell™ 96- Thermo Fisher RT
[0691] Well Plate, MaxiSorp™, flat bottom Scientific, 439454
[0692] Nunc® lid for microtiter plates Thermo Fisher RT
[0693]
[0694] Scientific, 263339
[0695] 1.1.2 Prepared reagents
[0696] Name Composition Storage
[0697] Wash buffer 0.05% Tween20 in PBS 4°C for up to 4 weeks Blocking buffer 2% BSA in PBS 4°C for up to 4 weeks Stop solution 1 N H2SO4RT, Chemical fume hood
[0698] 1.1.3 Equipment
[0699] Material Provider
[0700] ELISA plate reader Synergy
[0701] Plate shaker, Titramax 1000 Heidolph
[0702] Microplate Washer, BioTek BioTek
[0703]
[0704] 405LSRS1.2 MSD
[0705] 1.2.1 Materials
[0706] Material Provider Storage
[0707] PBS, lx, 500 ml Lonza, 14190-144 RT, 4°C
[0708] BSA Sigma Aldrich, A7030 4°C
[0709] Tween20 Sigma Aldrich, P1379 RT
[0710] Diluent 100, 1000 ml MSD, R50AA-3 4°C
[0711] Read Buffer B, 1000 ml MSD, R60AM-4 RT
[0712] Ultra-pure water ELGA 4°C
[0713] MSD GOLD SULFO-TAG NHS-Ester MSD, R31AA-1 4°C and -80°C
[0714] conjugation Pack 1
[0715] MAG003_TCER_WT (TCER4: wild Immatics, lot: 4°C
[0716] type MAG003) 1075581004, material
[0717] Nr.: 5004333
[0718] TCER_NR (non-recognizing) Immatics, batch 4°C
[0719] (TCER2: 100-NU(Varl7)- 23 / 04 / 2019 (MXCT,
[0720] R16PlC10HiAff#l-dsFcKO-GK) ProtL)
[0721] Human serum BiolVT -20°C
[0722] CCPro commercial human serum, CCPro, article Nr.: S-41- -20°C
[0723] M
[0724] Anti-idiotype Ab clone S Genscript -20°C / 4°C
[0725] (14C4B6B5, anti-recruiter)
[0726] Anti-idiotype Ab clone C Genscript -20°C / 4°C
[0727] (T5F2G7A8, anti-TCR)
[0728] EZ-Link SULFO-NHS-LC Biotin, no Thermo Fisher -20°C
[0729] weigh format Scientific, A39257
[0730] pHLA monomer MRF-1324 Immatics -80°C
[0731] MSD GOLD 96-well Small Spot SA MSD, L45SA-2 4 °C
[0732] SECTOR Plate Pack (5 Plate)
[0733] Sealing film ROTILABO® for Carl Roth, H769.1 RT
[0734] multiwell-plates, Polyester, Non- sterile, 25 pm
[0735] 96-well Conical 0.45 ml well PP Thermo Scientific, RT
[0736]
[0737] plate, natural 249944
[0738] The pHLA monomer was produced by protein refolding as previously described [2], In brief, HLA-A*02:01 heavy chain with a C-terminal Avi-tag and |32-microglobulin were separately produced in Escherichia coli as inclusion bodies which were purified and finally dissolved in chaotropic agents. Soluble pHLA monomers were refolded by rapid dilution of heavy chain, |32-microglobulin and the peptide. Refolded monomers were purified by size exclusion chromatography (SEC). After enzymatical biotinylation with BirA ligase, pHLA monomers were purified again by SEC.1.2.2 Prepared reagents
[0739] Name Composition Storage
[0740] Wash buffer 0.05%Tween20 in PBS 4°C for up to 4 weeks
[0741] Blocking buffer 3% BSA in PBS 4°C for up to 4 weeks
[0742] Human serum (HS) Pool Pool of 10 different BiolVT -20°C
[0743] HS in equal volumes
[0744]
[0745] 1.2.3 Equipment
[0746] Material Provider
[0747] Plate Reader, MESO QuickPlex SQ120 MSD
[0748] Plate shaker, Titramax 1000 Heidolph
[0749] Microplate Washer, e.g., BioTek 405LSRS BioTek
[0750]
[0751] 1.3 Sequences
[0752] Anti-idiotype Ab sequences
[0753] From all Ab clones herein provided (see Table 2), the hybridomas from the clones S (14C4B6B5), T (14C4B6E4), P (5F2G7A5), C (5F2G7A8) and B (14H7H4G12) were sequenced. In the case of clone S, a recombinant version was also generated with the specificity sequences. This recombinant version was tested in the MAG003 TCER PK assay and showed comparable performance to the hybridoma version (data not shown). The sequences of clone S and clone T hybridomas were exactly the same, hence, they produced the same Ab. For these hybridomas, the sequencing detected one heavy chain and two light chains. The one described as light chain 1 (only sequence shown) is the one that forms part of the correct Ab, as confirmed by downstream testing. This light chain 1 sequence was used to produce the recombinant version. The sequences of clone P and clone C hybridomas were also determined to be exactly the same. All sequences can be found below.
[0754] Table 2 Sequence of the variable domains of the hybridoma of clone S (14C4B6B5) and clone T (14C4B6E4)
[0755] SEQ ID Heavy chain (signal peptide and VH - signal peptide is underlined)
[0756] NO
[0757] 66 MKCSWVIFFLMAVVTGVNSEVQLQQSGAELVKPGTSVKLSCTVSGFNIKDTYLHWVKQRPE QGLEWIGKIDPTTGNSKYDPKFQGKATITSGTSPNTANLQLSSLTSEDTAVYYCAFGNDYWYF DVWGAGTTVTVSS
[0758] 67 Signal
[0759] peptide MKCSWVIFFLMAVVTGVNS
[0760] 47 EVQLQQSGAELVKPGTSVKLSCTVSGFNIKDTYLHWVKQRPEQGLEWIGKIDPTT GNSKYDPKFQGKATITSGTSPNTANLQLSSLTSEDTAVYYCAFGNDYWYFDVWG VH AGTTVTVSS
[0761] 68 FR1 EVQLQQSG AE LVKPGTSVKLSCTVSG FN 1 K
[0762] 40 CDR1 DTYLH
[0763]
[0764] 69 FR2 WVKQRPEQGLEWIG41 CDR2 KIDPTTGNSKYDPKFQG
[0765] 70 FR3 KATITSGTS P NTAN LQLSS LTS E DTAVYYC AF
[0766] 42 CDR3 GNDYWYFDV
[0767] 71 FR4 WGAGTTVTVSS
[0768] 72 AKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPA CH1- VLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPRDCGCKPCICTVP Hinge- EVSSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQP CH2- REEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRPKAPQ CH3 VYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDT DGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK
[0769] Light chain 1 (signal peptide and VL - signal peptide is underlined)
[0770] 73 MEKDTLl ■LWVLLLWVPGSTGDIVLTQSPASLAVSLGQRATISCRASESVDNYGISFIVINWFQQ KPGQPPI (LLIYGAANQGTGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQSKEVPWTFG GGTKLEI / \
[0771] 74 Signal
[0772] MEKDTLLLWVLLLWVPGSTG
[0773] peptide
[0774] 46 DIVLTQSPASLAVSLGQRATISCRASESVDNYGISFMNWFQQKPGQPPKLLIYGAA NQGTGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQSKEVPWTFGGGTKLEI VL K
[0775] 75 FR1 D 1 V LTQS PAS LAVS LG QR ATI SC
[0776] 43 CDR1 RASESVDNYGISFMN
[0777] 76 FR2 WFQQKPGQPPKLLIY
[0778] 44 CDR2 GAANQGT
[0779] 77 FR3 GVPARFSGSGSGTDFSLNIHPMEEDDTAMYFC
[0780] 45 CDR3 QQSKEVPWT
[0781] 78 FR4 FGGGTKLEIK
[0782] 79 RADAAPTVSI FPPSSEQLTSGG ASVVCFLN N FYPKDI N VKWKI DGSERQNGVLNS
[0783] CL
[0784]
[0785] WTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC
[0786] Recombinant version of clone S (14C4B6B5)
[0787] SEQ ID NO Heavy chain (signal peptide is underlined)
[0788] 80 MGWSCIILFLVATATGVHSEVQLQQSGAELVKPGTSVKLSCTVSGFNIKDTYLHWVKQR PEQGLEWIGKIDPTTGNSKYDPKFQGKATITSGTSPNTANLQLSSLTSEDTAVYYCAFGN DYWYFDVWGAGTTVTVSSAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVT WNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPR DCGCKPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEV HTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRPK APQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIIVIDTD GSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK* 49 EVQLQQSGAELVKPGTSVKLSCTVSGFNIKDTYLHWVKQRPEQGLEWIGKIDPTTGNSKY DPKFQGKATITSGTSPNTANLQLSSLTSEDTAVYYCAFGNDYWYFDVWGAGTTVTVSSA KTTPPSVYPLAPGSAAQ.TNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSD LYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPRDCGCKPCICTVPEVSSVFIFPPK PKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSVSEL PIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKVSLT
[0789]
[0790] CMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK
[0791] Light chain (signal peptide is underlined)
[0792] 81 MG WSCI 1 LFLVATATGVHSDI VLTQS PAS LAVS LGQR ATI SC R AS ES V D N YG 1 S F M N W FQ QKPGQPPKLLIYGAANQGTGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQSKEVP WTFGGGTKLEI KRADAAPTVSI FPPSSEQLTSGG ASVVCFLN N FYPKDI N VKWKI DGSER QNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC* 48 DIVLTQSPASLAVSLGQRATISCRASESVDNYGISFMNWFQQKPGQPPKLLIYGAANQGT GVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQSKEVPWTFGGGTKLEIKRADAAPT VSI FPPSSEQLTSGG ASVVCFLN N FYPKDI N VKWKI DGSERQNG VLNSWTDQDSKDSTYS
[0793]
[0794] MSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC
[0795] Hybridoma of clone P (5F2G7A5) and clone C (5F2G7A8)
[0796] SEQ Heavy chain (signal peptide and VH - signal peptide is underlined)
[0797] ID NO
[0798] 82 MGWSRIFLFLLSITAGVHCQVQLQQSGPELVKPGASVKISCKASGYAFNRSWMNWVKQRPGQ GLEWIGRIYPGDGDTRYNGKFKGKAKLTADISSSTAHMQLSSLTSEDSAVYFCAREVYYDMDY WGQGTSVTVSS
[0799] 83 Signal peptide MGWSRIFLFLLSITAGVHC
[0800] 63 QVQLQQSGPELVKPGASVKISCKASGYAFNR SWMNWVKQRPGQGLEWIGRIYPGDGDTR YNGKFKGKAKLTADISSSTAHMQLSSLTSEDS VH AVY FCAR E VYY D M DY WGQGTSVTVSS
[0801] 84 FR1 QVQLQQSGPELVKPGASVKISCKASGYAFN 50 CDR1 RSWMN
[0802] 85 FR2 WVKQRPGQGLEWIG
[0803] 51 CDR2 RIYPGDGDTRYNGKFKG
[0804] 86 FR3 KAKLTADISSSTAHMQLSSLTSEDSAVYFCAR 52 CDR3 EVYYDMDY
[0805] 87 FR4 WGQGTSVTVSS
[0806] Light chain (signal peptide and VL- signal peptide is underlined)
[0807] 88 MRFQVQVLGLLLLWISGAQCDVQITQSPSYLAASPGETITINCRTSKNIYKYLAWFQEKPGKTNK FLIYSGSTLQSGIPSRFSGSGSGTDFTLTISSLEPEDFAMYYCQQHNEYPWTFGGGTKLEIK
[0808] 89 Signal peptide MRFQVQVLGLLLLWISGAQC
[0809] 62 DVQITQSPSYLAASPG ETITI NCRTSKN IYKYL AWFQEKPGKTNKFLIYSGSTLQSGIPSRFSGS GSGTDFTLTISSLEPEDFAMYYCQQHNEYPW VL TFGGGTKLEIK
[0810] 90 FR1 DVQITQSPSYLAASPG ETITINC
[0811] 53 CDR1 RTSKNIYKYLA
[0812] 91 FR2 WFQEKPGKTNKFLIY
[0813] 54 CDR2 SGSTLQS
[0814] 92 FR3 GIPSRFSGSGSGTDFTLTISSLEPEDFAMYYC 55 CDR3 QQHNEYPWT
[0815]
[0816] 93 FR4 FGGGTKLEIKHybridoma of clone B (14H7H4G12)
[0817] SEQ Heavy chain (signal peptide and VH - signal peptide is underlined)
[0818] ID NO
[0819] 94 MGWSRIFLFLLSIAAGVHCQVQLQQSGPELVRPGASVKISCKGSGYAFSSSWMNWVKQRPGQ GLEWIGRIYPGDGDFKYNGKFKGKAILSADKSSSTAYMQLSSLTSVDSAVYFCAREGYYYDIGPW FASWGQGTLVTVSA
[0820] 95 Signal peptide MGWSRIFLFLLSIAAGVHC
[0821] 65 QVQLQQSGPELVRPGASVKISCKGSGYAFSSS WMNWVKQRPGQGLEWIGRIYPGDGDFKYN GKFKGKAILSADKSSSTAYMQLSSLTSVDSAVY VH FCAREGYYYDIGPWFASWGQGTLVTVSA
[0822] 96 FR1 QVQLQQSGPELVRPGASVKISCKGSGYAFS 56 CDR1 SSWMN
[0823] 97 FR2 WVKQRPGQGLEWIG
[0824] 57 CDR2 RIYPGDGDFKYNGKFKG
[0825] 98 FR3 KAILSADKSSSTAYMQLSSLTSVDSAVYFCAR 58 CDR3 EGYYYDIGPWFAS
[0826] 99 FR4 WGQGTLVTVSA
[0827] Light chain (signal peptide and VL- signal peptide is underlined)
[0828] 100 METDTLLLWVLLLWVPGSTGDIVLTQS PAS LTVS LGQR ATI AC R ASQS VSTS RYTYM H WYQQR PGQPPKLLIKFASNLESGVPARFSGSGSGTDFTLNIHPVEEEDSATYYCQHIWEIPWTFGGGTKL EIT
[0829] 101 Signal peptide METDTLLLWVLLLWVPGSTG
[0830] 64 D IV LTQS PAS LTVS LG QR ATI AC R ASQS VSTSR Y TYMHWYQQRPGQPPKLLIKFASNLESGVPAR FSGSGSGTDFTLNIHPVEEEDSATYYCQHIWEI VL PWTFGGGTKLEIT
[0831] 102 FR1 D 1 V LTQS PAS LTVS LG QR ATI AC
[0832] 59 CDR1 RASQSVSTSRYTYMH
[0833] 103 FR2 WYQQRPGQPPKLLIK
[0834] 60 CDR2 FASNLES
[0835] 104 FR3 GVPARFSGSGSGTDFTLNIHPVEEEDSATYYC 61 CDR3 QHIWEIPWT
[0836]
[0837] 105 FR4 FGGGTKLEITOverview of assay protocols during clinical PK assay development
[0838] ELISA
[0839] Assay
[0840] Assay setup Results
[0841] IDs
[0842] ELISA assays, selection of anti-idiotype Abs for MSP PK assay Direct ELISA
[0843] Direct ELISA format (PK-001-007) • Optimal secondary HRP conjugated Ab and its optima • Direct ELISA with TCER_WT as a capture reagent, and anticoncentration (cone.) was selected (based on signal-to-noise ratio) idiotype Ab and a detection secondary Ab conjugated to HRP. • TCER_WT optimal cone, were chosen for further developmen • Four detection HRP conjugated Abs were tested. (based on signal-to-noise ratio): 300 ng / mLand 1000 ng / mL.
[0844] • TCER_WT was titrated. • Anti-idiotype Ab cone, for sandwich format were chosen for furthe PK- • Anti-idiotype Abs (anti-recruiter and anti-TCR) were titrated. development: 300 ng / mL and 1000 ng / mL.
[0845] 001- Sandwich format (PK-008,009) • High background for anti-TCR Ab; hence, to be used as capture Ab 009 • TCER_WT was diluted in diluent or 50% HS (six healthy donors in sandwich assay.
[0846] (HD) pool). • Anti-TCR capture clones (P, C and B) and anti-recruiter detection • Anti-TCR Ab as capture (clones P, C and B) and anti-recruiter Ab clones (H, A, S, T) were chosen for sandwich format optimization.
[0847] as detection (clones H, A, S, T). Sandwich format
[0848] • The presence of HS resulted in higher background.
[0849] • Clones C (5F2G7A8) and S (14C4B6B5) were chosen for the MSD PK
[0850]
[0851] assay development.MSD Platform
[0852] Assay
[0853] Assay setup Results
[0854] IDs
[0855] PK assay preliminary assay, option 1 • Titration curve observed with diluent (no serum).
[0856] PK- • Sandwich format tested using clone C as capture (anti-TCR • No titration possible in 1:2 serum due to high background.
[0857] 010, domain) and clone S (anti-recruiter) as detection in 1:2 pooled
[0858] Oil HS (from six HD) and no serum (diluent only) (refer to option 1
[0859] from Figure 2).
[0860] Assay optimization, option 1 (switched Abs) • Reduction of the ECL signal at all TCER_WT cone, with respect to PK PK- • Capture and detection reagents were switched to optimize the 011.
[0861] 012 MSD assay. No serum (diluent only) and 1:2 or 1:5 dilutions in • The background remained high with HS.
[0862] pooled HS (from six HD) were used. • Controls yielded expected results.
[0863] Assay optimization, option 1 (switched Abs) • Background decreased with dilution of HS.
[0864] PK- • Additional serum dilutions included (1:4 and 1:8), along with • The background remained high with HS at all dilutions.
[0865] 013 1:2 dilution using pooled HS (from six HD) were tested and
[0866] compared to diluent.
[0867] Assay optimization, individual HS, option 1 (switched Abs) • Background is donor dependent.
[0868] PK- • Pooled HS deconvoluted. Individual HS from six HD used at 1:4,
[0869] 014,
[0870] 1:8 and 1:16 dilutions were tested and compared to diluent.
[0871] 015
[0872] Assay optimization, option 1 (switched Abs) • LowCross blocker showed no significant reduction in background.
[0873] • To reduce background, the following blockers were used • Heteroblock blocker (150 pg / ml) showed a significant reduction in PK- according to manufacturer recommendation with a HS that background and increase of detection range.
[0874] 016 showed high background (1:4 dilution):
[0875] 1. LowCross
[0876] 2. Heteroblock
[0877] Assay optimization, option 1 (switched Abs) • All new HS lots had a low background except for HS#16.
[0878] PK- • Ten new HS from different HD were tested using 1:4, 1:8 and • Background decreased with decreased HS cone.
[0879] 017
[0880]
[0881] 1:16 dilutions to identify HS with low matrix interference.Assay optimization, option 2 • Clone C Ab (anti-TCR domain) was used instead of Clone S as a • A new strategy was tested (refer to option 2 in Figure 2) using detection reagent; hence the experiment was repeated (PK-020). PK- a pool of HS from two HD, which yielded high background using
[0882] 018 the original assay strategy (option 1 in Figure 2). Serum
[0883] dilutions 1:2, 1:4 and 1:8 were tested, and pHLA monomer at
[0884] 6.6, 19.8 and 33 pg / mL was tested as capture reagent.
[0885] Assay optimization, option 1 (switched Abs) • Acceptable detection range observed using diluent and for a • Using diluent and three HS (1:4 dilution) that had led to low donors tested (n=3) although the background was dono PK- background in PK-017, the sensitivity of the assay with the dependent, indicating the need for further optimization.
[0886] 019
[0887] original assay strategy (option 1 in Figure 2, same as in PK-017)
[0888] was assessed using extended standard curves (23 calibrators).
[0889] Assay optimization, option 2 • Signal higher with lower pHLA monomer cone. (6.6 pg / mL).
[0890] • PK-018 was repeated using the same strategy (option 2 in • Signal higher with lower HS % (25%).
[0891] PK- Figure 2) using a pool of HS from two HD. Serum dilutions 1:2
[0892] 020
[0893] and 1:4 were tested, and pHLA monomer at 6.6, 19.8 and 33
[0894] pg / mL was tested as capture reagent.
[0895] Assay optimization, option 2 • Matrix effect was improved, option 2 (Figure 2) was selected fo • Employing option 2 (Figure 2), titration of pHLA monomer (6.6, further experiments.
[0896] PK- 1.98 and 0.66 pg / mL) and detection Ab clone S (100, 300 and • Selected cone, for detection Ab Clone S: 1 pg / mL, and capture pHLA 021 1000 ng / mL) was performed. Diluent and a HS that had led to monomer: 0.66 pg / mL.
[0897] high background using option 1 (Figure 2) (dilution 1:4) were • Minimum required dilution (MRD) established: 1:4 and used in tested. subsequent experiments (unless clarified differently). Sensitivity and dilutional linearity, option 2 Sensitivity
[0898] • Titration of TCER_WT in diluent and 3 different HS (HS#7, HS#8 • Lower limit of quantification (LLOQ): 0.1526 ng / mL.
[0899] and HS#9), using pHLA cone.: 0.66 pg / mLand detection reagent • Upper limit of quantification (ULOQ): 156.25 ng / mL.
[0900] (Clone S anti-recruiter) cone.: 1 pg / mL at the MRD (1:4). • Linear range: 0.1526 ng / mL - 156.25 ng / mL.
[0901] PK- • No blocking. Dilutional Linearity
[0902] 022
[0903] • Two negative controls (NC) were included: • The assay met the dilutional linearity acceptance criteria.
[0904] 3. NCI with TCER_NR (a TCER that does not bind to capture or • Bias between diluent and HS curves observed. Proposed solution detection reagents) in diluent and HS#7. use of a pool of different HS to prepare the calibration curve o
[0905]
[0906] 4. NC2 wo. pHLA coating in diluent. include different blocking steps.• Special analysis • No pHLA coating condition (NC2) yielded high background.
[0907] • Each HS curve as its own calibration curve for sensitivity • The NCI control yielded expected results.
[0908] assessment.
[0909] • HS#8 as calibration curve for dilutional linearity assessment
[0910] Selectivity and dilutional integrity, option 2 • The assay selectivity acceptance criteria were met.
[0911] Assay selectivity • The dilutional integrity acceptance criteria were not met. Thus, the • 2 TCER_WT cone.: 4 and 100 ng / mL. experiment was repeated in PK-033 using different conditions. • HS from 10 HD. • Blocking before (ON) and after coating with capture reagent will be • The cone, were calculated using a calibration curve prepared used to reduce possible matrix interference.
[0912] with 1:4 HS pool of 10 different HD (HS pool).
[0913] Dilutional integrity
[0914] • 100% individual sera was spiked above the ULOQ with
[0915] TCER_WT and sequentially diluted (1:5) in diluent.
[0916] PK- • Serum from two HD.
[0917] 023
[0918] • The cone, were calculated using a calibration curve in pure
[0919] diluent.
[0920] General
[0921] • Blocking before (ON) and after coating with capture reagent.
[0922] • QCs and three negative controls (all in diluent, cone.: 100, 4 and
[0923] 0.16 ng / mL) were included:
[0924] 5. NCI with TCER_NR.
[0925] 6. NC2 wo. pHLA coating.
[0926] 7. NC3 wo. pHLA coating and wo. blocking.
[0927] Dilutional integrity repetition, option 2 • The dilutional integrity acceptance criteria were met with this new • 100% individual sera was spiked above the ULOQ with diluent (1:4 HS pool).
[0928] TCER_WT and sequentially diluted (1:3) in 1:4 HS pool. • The calibration curve in 1:4 commercial CCPro HS was comparable PK- • Serum from three HD. to the curve in 1:4 HS pool and was considered as a possible 033 • The cone, were calculated using a calibration curve in 1:4 HS alternative to be used in the clinical trial. This commercial HS wa pool. tested in other experiments to confirm these results.
[0929] • A curve in 1:4 commercial CCPro HS was also included for
[0930]
[0931] comparison.• QCs and NC2 wo. pHLA coating (all in 1:4 HS pool, cone.: 100,
[0932] 11.11 and 1.235 ng / mL) were included.
[0933] Spike recovery, option 2 • The spike recovery assessment met the acceptance criteria.
[0934] • TCER_WT at 0.16, 4 and 100 ng / mL. • The calibration curve in 1:4 commercial CCPro HS was comparable • HS from five HD. to the curve in 1:4 HS pool.
[0935] PK- • The cone, were calculated using the HS pool calibration curve.
[0936] 024 • A curve in 1:4 commercial CCPro HS was also included for
[0937] comparison.
[0938] • NC2 wo. pHLA coating in commercial CCPro HS (cone.: 0.16, 4
[0939] and 100 ng / mL).
[0940] Short-term freeze thaw stability, option 2 • The short-term freeze thaw (3 cycles) stability acceptance criteria • 100% HS was spiked with TCER_WT at low, medium and high were met.
[0941] cone, for final cone, at MRD of 0.305, 4.883 and 78.125 ng / mL.
[0942] • HS from six HD were used.
[0943] PK- • Samples were analyzed fresh or following three freeze thaw
[0944] 026
[0945] cycles (-80 °C).
[0946] • The cone, were calculated using the HS pool calibration curve.
[0947] • QCs in HS pool (cone.: 0.305, 4.883 and 78.125 ng / mL).
[0948] • NC2 wo. pHLA coating in HS pool (cone.: 78.125 ng / mL).
[0949] Precision and accuracy, option 2 • Intra-assay precision and accuracy acceptance criteria were met.
[0950] • Operator 1. • This assay could not be included in the inter-assay analysis because . Controls: five TCER_WT cone. (0.0763, 0.305, 4.883, 78.125 and the TCER_WT cone, were changed in the subsequent experiment 312.5 ng / mL) in HS pool. to better fit the linear range.
[0951] • Eight replicates. • The calibration curve in 1:4 commercial CCPro HS was comparable PK- • The cone, were calculated using the HS pool calibration curve. to the curve in 1:4 HS pool.
[0952] 027 • A curve in commercial CCPro HS was also included for
[0953] comparison.
[0954] • Two NC were included in HS pool at 0.305, 4.883 and 78.125
[0955] ng / mL:
[0956] 8. NCI with TCER_NR.
[0957]
[0958] 9. NC2 wo. pHLA coating.Precision and accuracy, option 2 • Intra-assay precision and accuracy acceptance criteria were met.
[0959] • Operator 2. • The inter-assay analysis is performed after PK-035.
[0960] . Controls: five TCER_WT cone. (0.214, 0.643, 5.787, 52.083, • The calibration curve in 1:4 commercial CCPro HS was comparable 156.250 ng / mL) in HS pool. to the curve in 1:4 HS pool.
[0961] • Eight replicates.
[0962] PK- • The cone, were calculated using the HS pool calibration curve.
[0963] 028 • A curve in commercial CCPro HS was also included for
[0964] comparison.
[0965] • Two NC were included in HS pool at 0.643, 5.787 and 52.083
[0966] ng / mL:
[0967] 10. NCI with TCER_NR.
[0968] 11. NC2 wo. pHLA coating.
[0969] Precision and accuracy, option 2 • Intra-assay precision and accuracy acceptance criteria were no • Operator 2. met.
[0970] . Controls: five TCER_WT cone. (0.214, 0.643, 5.787, 52.083, • This analytical run was rejected and excluded from the inter-assay 156.250 ng / mL) in HS pool. precision assessment.
[0971] • The cone, were calculated using the HS pool calibration curve. • The calibration curve in 1:4 commercial CCPro HS was comparable PK- • A curve in commercial CCPro HS was also included for to the curve in 1:4 HS pool.
[0972] 029
[0973] comparison.
[0974] • Two NC were included in HS pool at 0.643, 5.787 and 52.083
[0975] ng / mL:
[0976] 12. NCI with TCER_NR.
[0977] 13. NC2 wo. pHLA coating.
[0978] Precision and accuracy, option 2 • Intra-assay precision and accuracy acceptance criteria were met in PK- • Same conditions as in PK-029. each assay.
[0979] 030, • Operator 2 performed PK-030 and 035. • Inter-assay precision and accuracy was evaluated using 031, • Operator 1 performed PK-031 and 032. experiments PK-028, 030, 031, 032, and 035.
[0980] 032 • As 3 experiments were performed by operator 2 and 2 experiment and by operator 1, the inter-operator precision and accuracy was also 035 included in the assessment, as it affected the total Bias and CV
[0981]
[0982] calculated for the inter-assay assessment.• The limit of detection (LOD) was calculated using PK-027, 028, 030
[0983] 031, 032, and 035 and it was compared retrospectively in these assays (see general run acceptance criteria section) meeting the acceptance criterion in every case.
[0984] LOD in HS pool at the MRD = 95.95.
[0985] • The calibration curves in 1:4 commercial CCPro HS were comparable to the curve in 1:4 HS pool, except for PK-035 and PK 030.
[0986] PK- Long-term stability at -80°C (baseline and one month), option 2 • The long-term stability validation results were considered as fina 025 assessment.
[0987] and
[0988] 034
[0989] PK- Long-term stability at -80°C (three, four, six and 12 months), • The long-term stability validation results were considered as fina 036, option 2 assessment.
[0990] 038,
[0991] 045
[0992] and
[0993] 052
[0994] PK- Long-term stability at -80°C (low to intermediate cone.; baseline, • The long-term stability validation results were considered as fina 037, one and two months ), option 2 assessment.
[0995] 043
[0996] and
[0997] 044
[0998] PK- Long-term stability at -20°C, option 2 • The long-term stability validation results were considered as fina 046 to assessment.
[0999] 051
[1000] pHLA short-term freeze thaw stability, option 2 • The pHLA reagent short-term stability acceptance criteria were me PK- • Fresh TCER_WT samples at low, medium and high cone, for for all freeze thaw cycles.
[1001] 042
[1002]
[1003] final cone, at MRD of 0.214, 5.790and 156.25 ng / mLwere used.• TCER_WT samples were analyzed using fresh pHLA reagent or
[1004] following one, two, three, four and six freeze thaw cycles (-80
[1005] °C).
[1006] • All samples were prepared in HS pool.
[1007] • QCs (TCER_WT) and two NC were included in HS pool at 0.214,
[1008] 5.79 and 156.25 ng / mL:
[1009] 14. NCI with TCER_NR.
[1010]
[1011] 15. NC2 wo. pHLA coating.
[1012] otes:
[1013] The pHLA concentrations informed in this Research Report are in some cases lower (0.66 x) relative to the concentrations that can be found in th process slips, calculation files and analysis files from each of these experiments. This is because an erroneous concentration was originally assigne to the pHLA reagent, and this was corrected after the assays were performed.
[1014] or PK-022-038 and PK-042 onwards, the following conditions apply (unless specified differently):
[1015] Capture reagent (pHLA monomer): 0.66 pg / mL.
[1016] Detection reagent (anti-idiotype Ab Clone S): 1 pg / mL.
[1017] HS was used at the MRD (1:4).
[1018] The calibration curves and the QCs with TCER_WT (when included) met the acceptance criteria (described in general run acceptance criteri section).
[1019] The NCs yielded expected results.
[1020] Blocking before (ON) and after coating with capture reagent.
[1021] or all assays:
[1022] Duplicates were used, unless specified differently.3 Results
[1023] 3.1 Anti-idiotype Ab generation for MAG003 TCER
[1024] MAG003 TCER variants for the generation for murine immunization and Ab selection were used. An immunization phase was performed, where animals were immunized with a variant of the MAG003 TCER, where the human constant domains CH2-CH3 had been replaced with murine lgG2a constant domains (IMA-IVI07-mFc, see below), according to a detailed schedule involving primary immunization, multiple boosts, and test bleeds to monitor immune response through ELISA tests. Following the final boost, cell fusion was performed using electro-fusion, and hybridoma clones were screened via ELISA to identify positive binders. An overview of utilized antigens is provided in Figure 3.
[1025] Confirmatory screenings and affinity rankings were conducted. The best clones were selected and these were then expanded and frozen. Subcloning ensured monoclonality, with selected subclones being cryopreserved. Ab production involved purifying antibodies from selected clones, followed by quality control tests such as SDS-PAGE and ELISA. Purified antibodies from different clones were analyzed for their performance in different PK assay designs and final clones were selected.
[1026] The sequencing of the final selected antibodies was carried out to determine the amino acid sequence of the variable regions, and a sequencing report was provided. The deliverables included antiserum samples, cultured supernatants, frozen cell vials, purified antibodies, and sequencing reports. One Ab sequence was recombinantly expressed in the ExpiCHO-S system with transient plasmid transfection to generate a recombinant version of one selected Ab.
[1027] The anti-recruiter antibody 14C4B6B5 recognized only the variable domains VL and VH of the TCER, but not the constant domains or the variable domains of the TCR (Figure 4).
[1028] Anti-TCR antibodies specifically bound to the variable domains of the MAG003 TCR and did not recognize the different tested TCR (Figure 5).
[1029] Binding of the anti-TCR antibodies was further characterized by blocking experiments. For this purpose, the soluble pHLA was added to the above-described ELISA and a reduction of the signal was observed (data not shown). This indicates that the binding of these antibodies is sterically hindered by the binding of pHLA to the variable domains of the TCR and that the CDRs might be part of the recognized epitope.
[1030] The following sequences were used for immunization and selection:SEQ Description / Sequence
[1031] ID Region /
[1032] NO: Domain
[1033] IMA-M07-mFc; QIQMTQSPSSLSASVGDRVTITCSATSSVSYMHWYQQKPGKAPKRWIYD 106 Immunogen; TSKLASGVPSRFSGSGSGTDYTLTISSLQPEDAATYYCQQWSSNPLTFGG Variable regions GTKVEIKGGGSGGGGDAGVIQSPRHEVTEMGQEVTLRCKPIPGHDYLF (TCR and mAb) of WYRQTMMRGLELLFYFCYGTPCDDSGMPEDRFSAKMPNASFSTLKIQP the MAG003 TCER SEPRDSAVYFCASRADTGELFFGEGSRLTVLEPRGPTIKPCPPCKCPAPNLL fused to mouse GGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHT lgG2a Fc domains; AQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERT heavy_chain_l | ISKPKGSVRAPQVYVLPPCEEEMTKKQVTLWCMVTDFMPEDIYVEWTN NGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGL HNHHTTKSFSRTPGK
[1034] 107 IMA-M07-mFc; EDVEQSLFLSVREGDSVVINCTYTDSSSTYLYWYKQEPGKGLQLLTYIYSSQ Immunogen; DQKQDQRLTVLLNKKDKHLSLRIADTQTGDSAIYFCAEMTSESKIIFGSGT Variable regions RLSIRPGGGSGGGGEVQLVQSGAEVKKPGASVKVSCKASGYKFTSYVMH (TCR and mAb) of WV RQAPG QG LE W M G Yl N PY N D VTKY AE KFQG R VTLTS DTSTSTAY MEL the MAG003 TCER SSLRSEDTAVHYCARGSYYDYEGFVYWGQGTLVTVSSEPRGPTIKPCPPC fused to mouse KCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWF lgG2a Fc domains; VN N VEVHTAQ.TQ.TH REDYNSTLRVVSALPIQHQD WMSG KEFKCKVN N heavy_chain_2 KDLPAPIERTISKPKGSVRAPQVCVLPPPEEEMTKKQVTLSCAVTDFMPE DIYVEWTNNGKTELNYKNTEPVLDSDGSYFMVSKLRVEKKNWVERNSYS CSVVHEGLHNHHTTKSFSRTPGK
[1035] 108 IMA-M11,
[1036] Positive screen EDVEQSLFLSVREGDSVVINCTYTDSSSTYLYWYKQEPGKGLQLLTYIYSSQ for anti-TCR DQKQDQRLTVLLNKKDKHLSLRIADTQTGDSAIYFCAEMTSESKIIFGSGT mAbs; RLSIRPGGGSGGGGDIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNW TCER molecule YQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDIATYFC based on TCR of QQGQTLPWTFGQGTKVEIKEPKSSDKTHTCPPCPAPPVAGPSVFLFPPKP MAG003 TCER, KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ different VH / VL; YQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPRE heavy_chain_l | PQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTT PPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL SP
[1037] 109 IMA-M11,
[1038] Positive screen EVQLVQSGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQGLEW for anti-TCR M G LI N PQKG VSTYAQKFQD R VTLTV D KSTSTAYM E LSS LRSE DTAVYYC A mAbs; RSGYYGDSDWYFDVWGQGTLVTVSSGGGSGGGGDAGVIQSPRHEVTE TCER molecule MGQEVTLRCKPIPGHDYLFWYRQ.TMMRGLELLFYFCYGTPCDDSGMPE based on TCR of DRFSAKMPNASFSTLKIQPSEPRDSAVYFCASRADTGELFFGEGSRLTVLE MAG003 TCER, PKSSDKTHTCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH different VH / VL; EDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDWLN heavy_chain_2 | GKEYKCKVSNKALPASIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLS CAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSP
[1039] 110 TPP-93, Negative ILNVEQSPQSLHVQEGDSTNFTCSFPVKEFQDLHWYRKETAKSPEFLFYF
[1040]
[1041] screen for anti- GPYGKEKKKGRISATLNTKEGYSYLYITDSQPEDSATYLCALYNNNDMRFTCR and anti- GAGTRLTVKPGGGSGGGGDIQMTQSPSSLSASVGDRVTITCRASQDIRN mAb, YLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDI heavy_chain_l | ATYFCQQGQTLPWTFGQGTKVEIKEPKSSDKTHTCPPCPAPPVAGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP REEQYQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKG QPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP
[1042] Ill TPP-93, Negative EVQLVQSGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQGLEW screen for anti- M G LI N PYKGVSTY AQKFQD R VTLTVD KSTSTAY MELSSLRSE DTAVYYC A TCR and anti- RSGYYGDSDWYFDVWGQGTLVTVSSGGGSGGGGGVIQSPRHLVTEMG mAb, QEVTLRCKPISGHNSLFWYRETPMQGLELLIYFQNTAVIDDSGMPEDRFS heavy_chain_2 | AKMPNASFSTLKIQPSEPRDSAVYFCASSPGATDTQYFGPGTRLTVLEPKS SDKTHTCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDWLNGKE YKCKVSNKALPASIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSP
[1043] 112 TPP-79, Negative QIQMTQSPSSLSASVGDRVTITCSATSSVSYMHWYQQKPGKAPKRWIYD screen for anti- TSKLASGVPSRFSGSGSGTDYTLTISSLQPEDAATYYCQQWSSNPLTFGG TCR, positive GTKVEIKGGGSGGGGGVIQSPRHLVTEMGQEVTLRCKPISGHNSLFWYR screen for anti- ETPMQGLELLIYFQNTAVIDDSGMPEDRFSAKMPNASFSTLKIQPSEPRD mAb; SAVYFCASSPGATDTQYFGPGTRLTVLEPKSSDKTHTCPPCPAPPVAGPS heavy_chain_l | VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKA KGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPE NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY TQKSLSLSP
[1044] 113 TPP-79, Negative ILNVEQSPQSLHVQEGDSTNFTCSFPVKEFQDLHWYRKETAKSPEFLFYF screen for anti- GPYGKEKKKGRISATLNTKEGYSYLYITDSQPEDSATYLCALYNNNDMRF TCR, positive GAGTRLTVKPGGGSGGGGEVQLVQSGAEVKKPGASVKVSCKASGYKFTS screen for anti- YVMHWVRQAPGQGLEWMGYINPYNDVTKYAEKFQGRVTLTSDTSTST mAb; AYMELSSLRSEDTAVHYCARGSYYDYEGFVYWGQGTLVTVSSEPKSSDKT heavy_chain_2 | HTCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK FNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPASIEKTISK AKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNH
[1045]
[1046] YTQKSLSLSP
[1047] 3.2 ELISA assays
[1048] These assays were conducted to select the best performing anti-idiotype Ab combinations and concentrations for detection of MAG003 TCER in a sandwich format, for the subsequent development of the PK assay using the MSD platform. Capture, detection reagents and TCER_WT were titrated to select the optimal anti-idiotype pairs.Ten clones recognizing the TCR domain and 12 clones recognizing the recruiter domain were provided by Genscript. Seven clones (indicated with letters in Figure 6 and listed in Table 2) were preselected for the ELISA sandwich format tests (PK-008 and 009), based on affinity data (Figure 6). Figure 7 depicts the summary of the ELISA results using clones S and T as detection clones, showing that the combination of clone C (capture, 5F2G7A8) and clone S (detection, 14C4B6B5) yielded the widest detection range. After testing all combinations, Clones C and S were chosen for the MSD PK assay development.
[1049] Of note, the hybridomas producing the clones S, T, P, C and B (Table 2) were sequenced at a later timepoint. The sequences of clone S and clone T hybridomas were exactly the same, hence, they produced the same Ab. The sequences of clone P and clone C hybridomas were also determined to be exactly the same. This does not alter the performance of the assay.
[1050] Table 1: Anti-idiotype antibodies recognizing MAG003 TCER selected for assay development
[1051] Antibodies recognizing the recruiter
[1052] domain
[1053] Clone-ID Short name
[1054] 13A11C5A3 Clone H
[1055] 13A11C5B6 Clone A
[1056] 14C4B6B5 Clone S
[1057] 14C4B6E4 Clone T
[1058] Antibodies recognizing TCR domain
[1059] Clone-ID Short name
[1060] 5F2G7A5 Clone P
[1061] 5F2G7A8 Clone C
[1062] 14H7H4G12 Clone B
[1063] 3.3 PK assay strategy establishment
[1064] The same sandwich format used in ELISA was tested in experiments with the MSD platform (PK-010-015). A matrix effect was observed with certain HS, regardless of capture and detection reagent concentrations (e.g. PK-014 in Figure 8). In order to reduce the matrix effect included switching the anti-idiotype Abs, changing blocking steps, testing different blockers, testing different serum dilutions and deconvoluting pooled serum to pinpoint donor-dependent differences. As these approaches could be further improved (e.g., Figure 8) to fulfill the high internal standards, a new strategy using pHLA monomer as capture reagent was tested (PK-020) showing lower background with a pool of two HS that had individually led to high background before (pool of HS#3 and HS#5) (Figure 9). In PK-021, this assay was further optimized (data not shown) and the experimental conditions were established:
[1065] • Detection reagent (anti-idiotype Ab Clone S): 1 pg / mL
[1066] • Capture reagent (pHLA monomer): 0.66 pg / mL
[1067] • MRD: 1:43.4 General run acceptance criteria
[1068] The following run acceptance criteria were applied to all analytical runs unless otherwise specified in the different performance assessments. Some criteria were adjusted to standardize the assessment of all parameters.
[1069] Unless indicated otherwise, the acceptance criteria for the calibration curve were the following:
[1070] • Standards: CV < 20% and Bias ± 25%
[1071] • ULOQ: CV < 20% and Bias ± 25%
[1072] • LLOQ: CV < 30% and Bias ± 30%
[1073] • Standards beyond the established LOQs were discarded.
[1074] • A four-parameter logistic (4PL) model was used for curve fitting.
[1075] In PK-034, a new criterion was introduced for the negative controls: each NC mean ECL + 2*SD < mean ECL of the lowest standard in the curve (i.e., anchor point). At least 80% of the NC samples must meet this criterion, and the samples not meeting it cannot correspond to the same controls in different experiments (e.g., the highest NC concentration of NCI or NC2).
[1076] The acceptance criteria of the TCER_WT QC samples in different concentrations were CV < 20% and Bias ± 25%. At least 80% of the QC samples must meet this criterion, and the samples not meeting this criterion cannot correspond to the same controls in different experiments (e.g. the highest concentration).
[1077] Unless otherwise specified, the QCs and NCs will only be discussed in instances of performance parameter-specific analysis.
[1078] The acceptance criterion applied to the LOD (LOD = blank mean ECL + 2*SD < LLOQ mean ECL) is only required in the sensitivity assessment and is not part of the run acceptance criteria. However, as it must be calculated with all acceptable analytical runs (in the same conditions and diluent), it could not be assessed at this point (PK-022). We defined a LOD using all acceptable precision and accuracy assays (PK-027, 028, 030, 031, 032, and 035) as they used the same calibration curve in HS pool at the MRD.
[1079] 3.5 PK assay performance assessment
[1080] 3.5.1 Sensitivity and dilutional linearity
[1081] PK-022 was performed to assess sensitivity and dilutional linearity. Regarding sensitivity, the goal was to calculate the ULOQ and LLOQ and to define the linear range. Three standard curves of TCER_WT diluted in serum from three individual HD (HS#7, 8 and 9) at the MRD (1:4) and one with pure diluent were used in this assay. An "intra-curve LOD" (using the blanks associated witheach HS or diluent) was calculated for each curve and met the acceptance criterion (blank mean ECL + 2*SD < LLOQ mean ECL) (see general run acceptance criteria section). The U / LLOQ were determined for each curve in HS (using the calibration curve criteria defined above) and the most stringent values were selected as preliminary LOQs (LLOQ = 0.0763 ng / mL, ULOQ = 312 ng / mL). However, this range was further reduced by the dilutional linearity range as explained below. Of note, the CV scatter plot was not created as it was not necessary for the assessment of the sensitivity.
[1082] Dilutional linearity was evaluated with the same three standard curves of TCER_WT diluted in serum from three HD (HS#7, 8 and 9) at the MRD (1:4). As we had observed a donor-dependent background relative to standard curve prepared in diluent, we used one of the HS curves as calibration curve (HS#8). The first two criteria for dilutional linearity were met (1) Mean ECL count for spiked samples above ULOQ must be above the mean ECL count value of the ULOQ standard, 2) Mean back-calculated concentrations must have a CV < 20.0% at each dilution within the assay range). The third criterion was used to define the limits of the dilutional linearity range: Precision (CV) and accuracy (Bias) of the overall mean measurements (with the exception of the sample above the ULOQ) must have CV < 20.0% and Bias ± 25.0%. The CVs were > 20% only in the values previously defined as ULOQ and LLOQ, and the Bias was > 25% only at the ULOQ. Hence, these two values were excluded and final LOQs were defined: LLOQ = 0.1526 ng / mL and ULOQ = 156.25 ng / mL, as within this range, the assay exhibited dilutional linearity. Figure 10 shows the calibration curve in HS#8 at the MRD as an example (the other curves are not shown).
[1083] A matrix effect was observed when comparing calibration curves of TCER_WT in serum from individual HD to that of TCER_WT in diluent. Thus, it was decided to test HS pool (10 HD, at the MRD: 1:4 dilution) as diluent for the calibration curve, QCs and NCs, where applicable to reduce observed matrix effect.
[1084] 3.5.2 Assay selectivity and dilutional integrity
[1085] Assay selectivity was analyzed to assess the detection and quantification of TCER_WT in the presence of HS in PK-023. Two TCER_WT concentrations (4 and 100 ng / mL) plus a blank and individual HS from 10 HD at the MRD were tested (30 control samples). A calibration curve in HS pool (10 HD, at the MRD) was used to calculate the controls' concentrations, and the Bias was decreased relative to the standard curve prepared in pure diluent, indicating that HS pool was a more appropriate diluent. The control samples signals with the same concentration were all clustered, showing small differences among different HS (data not shown). The assay met the acceptance criteria for selectivity.
[1086] Two blocking steps (before (ON) and after coating with capture reagent) were introduced in PK-023 to reduce background effects possibly caused by unspecific interaction between serum components and the plate or the capture reagent. Although the additional blocking step did noteliminate the matrix effects we had observed (data not shown), it was nevertheless conserved in the procedure to reduce other potential unspecific protein-protein interactions.
[1087] In parallel, dilutional integrity was tested by spiking HS (100% HS#15 or HS#16) with TCER_WT above the ULOQ (500 ng / mL) and then sequentially diluting it in diluent (DF: 5). When a standard curve in pure diluent was used to back-calculate the TCER concentrations of the dilutional integrity control samples, the first acceptance criterion was met: calculated concentrations CV < 20.0% for each dilution within the assay range. However, the second criterion was not met (the overall mean measurement of the dilutional integrity control samples with both HS within the dilution linearity range must have CV < 20.0% and Bias within ± 25.0%). It was hypothesized that matrix effect could be directly correlated to serum percentage. In other words, control samples closer to the LLOQ exhibited decreased matrix effect relative to samples close to or above the ULOQ. This was evidenced in experiment PK-023, in which the control samples at low concentrations showed ECL values similar to the ones of the standard curve in diluent, while the control samples with concentrations close to the ULOQ and above led to ECL values closer to the standard curve in HS pool (at the MRD) (data not shown).
[1088] To address this, the assay was repeated (PK-033). In this assay, pure HS from three different HD (100% #14, #15 or #16) were spiked with TCER_WT above the ULOQ (300 ng / mL) and then sequentially diluted (DF: 3) in HS pool at a 1:4 dilution (instead of pure diluent). In this way, the final serum percentage was above 25% in all control samples, even in the lowest concentration of the dilutional integrity controls. When using a calibration curve in HS pool at the MRD to calculate the controls' concentrations, the dilutional integrity criteria were met for all TCER concentrations, demonstrating that matrix interference impacted this performance parameter (data not shown).
[1089] In PK-033, a calibration curve in commercial CCPro HS at the MRD was tested as a possible alternative to the HS pool calibration curve, and both curves led to similar ECL values (data not shown). This curve was included in other assays to confirm these results (see assay overview).
[1090] 3.5.3 Spike recovery
[1091] Spike recovery analysis was performed in PK-024 to assess whether TCER_WT detection is affected by differences in the standard curve diluent and sample matrix (serum). The spike recovery control samples were generated spiking TCER_WT at three concentrations within the linear range (0.16, 4 and 100 ng / mL, plus blank) in HS from five different HD at the MRD. The acceptance criteria applied was: at least 80% of the spike recovery controls samples' back-calculated concentrations must be within Bias ± 25.0%. Using a standard curve in HS pool at the MRD, these acceptance criteria were met, as only 1 out of 15 controls had | Bias | > 25% (data not shown).3.5.4 Precision and accuracy
[1092] PK-027-032 and 035 were performed to assess intra-assay, inter-assay and inter-operator precision and accuracy. The calculations were performed with calibration curves prepared in HS pool at the MRD. Five concentrations of TCER_WT spanning the linear range were included as controls in each assay. Experiments PK-027 and 028 included eight replicates for intra-assay precision assessment. Samples in all other experiments were performed in duplicates. All runs with the exception of PK-029 met the intra-assay precision and accuracy acceptance criteria (CV < 20% and Bias ± 25%). In the case of PK-029, control samples did not meet acceptance criteria. This experiment was repeated by the same operator in experiment PK-035 and the acceptance criteria were met.
[1093] As PK-027 was performed before the establishment of the LOQs, the highest and lowest concentrations used in the precision and accuracy controls were beyond the linear range of the assay. Therefore, the calibration curve and controls concentrations were changed to fit the linear range from PK-028 onwards and, consequently, PK-027 could not be included in the inter-assay analysis because it employed different concentrations than the rest of the experiments. Refer to Table 3 for summary of results.
[1094] Table 3: Intra-assay precision and accuracy analysis, PK-028. The values in bold were used to evaluate the acceptance criteria of this analysis.
[1095] Control nominal Calculated cone, Calculated
[1096] Recovery (%) Bias (%) cone. (ng / mL) mean (ng / mL) Cone. CV (%)
[1097] 156.250 118.744 9.503 75.996 -24.004 52.083 45.139 4.660 86.667 -13.333 5.787 5.852 3.456 101.124 1.124 0.643 0.667 4.891 103.743 3.743
[1098]
[1099] 0.214 0.244 6.149 113.874 13.874
[1100] PK-031, 032 (performed by operator 1) and PK-028, 030 and 035 (performed by operator 2) were used to perform the inter-assay analysis. Criteria:
[1101] 1) Overall mean concentration of the control samples (all assays) must have CV < 20% and Bias ± 25%.
[1102] 2) Total error of the control samples (all assays) = CV + | Bias | must be < 30% or, at the ULOQ and LLOQ< 40%.
[1103] As seen in Table 3, these criteria were met with all controls, and considering the experiments were performed by two different operators, we also concluded that the assay had sufficient inter-operator precision and accuracy.
[1104] Table 3: Inter-assay precision and accuracy analysis. The values in bold were used to evaluate the acceptance criteria of this analysis. Of note, as the first control (cone.: 156.250 ng / mL)coincides with the ULOQ, its cut-off for the total error is 40%, hence, a value of total error = 33.0% meets this acceptance criterion.
[1105] Calculated
[1106] Control Calculated
[1107] cone, Calculated Recovery Bias mean | Bias mean| Total nominal cone. CV
[1108] mean cone. SD mean (%) (%) (%) error (%) cone. (ng / mL) (%)
[1109] (ng / mL)
[1110] 156.250 134.740 25.959 19.266 86.234 -13.766 13.766 33.032 52.083 44.591 1.729 3.879 85.614 -14.386 14.386 18.264 5.787 5.523 0.465 8.412 95.440 -4.560 4.560 12.972 0.643 0.630 0.072 11.386 98.053 -1.947 1.947 13.334
[1111]
[1112] 0.214 0.219 0.032 14.630 102.168 2.168 2.168 16.798
[1113] The concentrations used in the calibration curve, for NCI, NC2 and for QCs were established for future assays (see Table 5).
[1114] The LOD was calculated using all acceptable precision and accuracy assays (PK-027, 028, 030, 031, 032, and 035) as they used the same calibration curves in HS pool at the MRD, and it was established at 95.95 ECL. The LOD criterion was retrospectively assessed and was met for aforementioned assays.
[1115] In experiments PK-024, PK-025, PK-027, 028, 029, 030, 031, 032, PK-033, PK-034 and 035, a calibration curve in commercial CCPro HS at the MRD was included. This curve was comparable to the HS pool curve in the linear range (data not shown), except for PK-30 and PK-035 (due to an unidentified cause), indicating it could be used as an alternative.
[1116] 3.5.5 Short-term freeze / thaw TCER stability
[1117] In PK-026, we analyzed whether multiple rounds of freezing (-80 °C) and thawing affected the stability of the detected TCER_WT when spiked into pure HS. The samples, prepared in serum from six individual HD, were diluted at the MRD (1:4) to reach three concentrations spanning the linear range. Two conditions were tested: fresh / baseline and three-times frozen / thawed. All 18 conditions (six HS in three concentrations) met the acceptance criteria (at least 80% spiked individual HS must exhibit CV < 20% and be within ± 25% of Bias relative to the baseline timepoint) showing that TCER_WT is stable in these conditions (data not shown).
[1118] A further different acceptance criteria for stability was suggested: the assay has to meet the intra-assay CV and Bias < 20% criteria (comparison to nominal concentrations), and there is no need to compare baseline with the different timepoints. 2 / 3 sets of each concentration must pass, this is 66.7% (4 / 6 sets in our case as we test 6 different HS samples). These new criteria were also met (data not shown), were used to analyze the subsequent stability experiments and the previous criteria were disregarded.3.5.6 Long-term freeze / thaw TCER stability at -80 °C
[1119] PK-025, 034, 036, 038, 045 and 052 were performed to assess the long-term stability of TCER_WT frozen at -80 °C in pure HS for different periods of time. HS from six different HD were spiked with TCER_WT to reach three concentrations spanning the dilutional linearity range when diluted to the MRD (1:4).
[1120] The same stability criteria described in PK-026 were used for all long-term stability experiments: the assay has to meet the intra-assay CV and Bias < 20% criteria (comparison to nominal concentrations), and there is no need to compare baseline with the different timepoints. 2 / 3 sets of each concentration must pass, i.e. 66.7% (4 / 6 sets need to meet the criteria in this case as we test 6 different HS).
[1121] The baseline timepoint (PK-025) was evaluated using the same criteria as the stability timepoints and only one set did not meet the Bias criterion (while all met the CV criterion). Hence, all concentrations met the acceptance criteria. In PK-034 we assessed the stability at one month. All samples met the CV criterion but 3 samples did not meet the Bias criterion and these were all at the 100 ng / mL concentration: 3 / 6 sets meet the criteria. Hence, 0.16 and 4 ng / mL meet the criteria but not 100 ng / mL. When assessing the three-month timepoint (PK-036), all samples meet the CV criteria and only one set at 0.16 ng / mL and another one at 100 ng / mL did not meet the Bias criteria. Therefore, the stability criteria is met at this timepoint. As the effect associated with 100 ng / mL observed at one month is not observed here, we consider it was a random error not associated with stability. Furthermore, at four months (PK-038), all sets met the CV and Bias criteria confirming this hypothesis. At six months (PK-045), one sample did not meet the CV criterion and three samples did not meet the Bias criterion (all with Bias lower than 121% | ). At 100 and 016 ng / mL, 4 / 6 sets (2 / 3) meet the criteria and at 4 ng / mL, all sets meet the criteria (data not shown). Therefore, stability is also confirmed at the six-month timepoint. The stability was also assessed at 12 months (PK-052). All samples meet the CV criterion and all the 0.16 and 4 ng / mL samples met the Bias criterion. However, 4 / 6 samples at 100 ng / mL did not meet the Bias criterion (although only one had a | Bias | > 25%) (data not shown). In conclusion, the stability criteria was met for 0.16 and 4 ng / mL at one year but not for 100 ng / mL (after MRD). As the samples that did not pass were so close to the threshold, we could have repeated this last assay twice to assess whether these were random effects. However, the long term stability was later repeated during validation, so these repetitions were not necessary during development. Of note, long-term stability forTCER_WT in HS samples was demonstrated for up to 12 months (364 days) during validation for samples stored at -75°C±15°C (data not shown here).
[1122] 3.5.7 Long-term freeze / thaw TCER stability at -20 °C
[1123] As there was a possibility that some sites did not have -80 °C freezers, long-term stability of TCER_WT in pure HS was also assessed at -20 °C in PK-046 to 051. HS from six different HD were spiked with TCER_WT to reach different concentrations spanning the dilutional linearity range when diluted to the MRD (1:4). At this temperature, we obtained variable results in-house andwe concluded the experiments should be repeated. As the stability tests at -20°C were performed in parallel for validation, these repetitions were not conducted. The long-term stability for TCER_WT in HS samples was demonstrated for up to 12 months (364 days) during validation for samples stored at -20°C±5°C (data not shown here).
[1124] 3.5.8 Short-term freeze / thaw pHLA stability
[1125] In PK-042, we analyzed whether multiple rounds of freezing (-80 °C) and thawing affected the stability of the pHLA reagent. A new aliquot of pHLA was thawed and subaliquots were prepared (at the stock concentration) for the different conditions. One aliquot was kept thawed, and others subjected to: lx, 2x, 3x, 4x and 6x freeze / thaw cycles. Then these pHLA conditions were tested in three TCER_WT concentrations: 156.25, 5.79 and 0.214 ng / mL at the MRD (25% HS pool).
[1126] As in previous stability tests, the acceptance criteria was: intra-assay CV and Bias < 20% (comparison to nominal concentrations), and no need to compare baseline / fresh with the different conditions. 2 / 3 sets of each concentration must pass (only one set per concentration per condition here). In conclusion, all samples met the criteria showing that the pHLA reagent is stable after up to six freeze / thaw cycles.
[1127] 3.5.9 Summary
[1128] In summary, the PK assay for detection and quantification of TCER_WT was successfully developed and characterized. The performance parameters were assessed and met the predefined or adjusted acceptance criteria. Furthermore, the stability of the TCER in HS upon repeated freeze / thaw cycles was confirmed. After this development, a comprehensive validation was performed for MAG003 TCER PK assay and the tested performance criteria were also fulfilled. Of note, the long-term stability was confirmed in certain ranges during development and in validation up to 12 months at -20°C±5°C and -75°C±15°C. Below, table 5 and 6 show certain exemplary performance parameters and assay conditions established during the MAG003 TCER PK assay development.
[1129] Table 5: MAG003 TCER PK assay development and assay performance parameters
[1130] Parameter _ Value / conditions
[1131] Capture pHLA monomer final cone. 0.66 pg / mL
[1132] Detection sulfo-tagged Ab (Clone S) 1 Pg / mL
[1133] final cone.
[1134] MAG003 TCER calibration curve Cone.: 156.250 ng / mL in HS pool at the MRD, DF: 3, 7 cone. + blank
[1135] NCI (TCER_NR), NC2 (no pHLA coating), Cone.: 52.083, 5.787 and 0.643 ng / mL in HS QCs (MAG003 TCER) pool at the MRD
[1136] ULOQ 156.25 ng / mL
[1137] LLOQ 0.1526 ng / mL
[1138] LOD with HS pool at the MRD 95.95 (ECL)(calculated with all acceptable precision
[1139] and accuracy performance assays)
[1140] MRD 1:4
[1141] Diluent of choice 25% HS pool in Diluent 100
[1142] Capture pHLA monomer volume 25 pL
[1143] Analyte volume 50 pL
[1144] Detection Ab volume 25 pL
[1145] HS pool: pooled human serum from 10 HD.
[1146] Note: the TCER concentrations are after applying the MRD, hence the concentration in serum are 4x higher.
[1147] Table 6: Process overview MAG003 TCER MSD PK assay
[1148] Option 1 Option 2
[1149] Day 1: Blocking overnight, 4°C Day 1: Blocking for lh, at RT, on a plate shaker Day 2: Coating for lh, at RT, on a plate shaker Day 1: Coating overnight, at 4°C
[1150] Day 2: Blocking for lh, at RT, on a plate shaker Day 2: Blocking for lh, at RT, on a plate shaker Day 2: Standards / Controls / Analytes, for lh, at RT, on Day 2: Standards / Controls / Analytes, for lh, at a plate shaker RT, on a plate shaker
[1151] Day 2: Sulfo-TAG detection Ab, for 5 min, at RT, on a Day 2: Sulfo-TAG detection Ab, for 5 min, at RT, plate shaker on a plate shaker
[1152] Day 2: Read Buffer, read within 5-10 minutes Day 2: Read Buffer, read within 5-10 minutes
[1153]
[1154] 3.6 The PK assay was performed with another therapeutic protein
[1155] The above provided assays were also used for the detection of PRAME004 TCER to be used in clinical trials.
[1156] 4 Anti-drug antibody (ADA) clinical assay
[1157] The same anti-idiotype Ab targeting the recruiter domain of MAG003 TCER used for detection in the MAG003 / PRAME004 TCER PK assays (clone S: 14C4B6B5 in Table 2) was used as positive control in the development of an ADA assay for MAG003 TCER. Using patient sera, the ADA assay can detect potential antibodies generated by the patient's immune system against the infused TCER, assessing its immunogenicity. This immune response is unwanted and could have effects on PK, pharmacodynamics and safety.
[1158] The MAG003 TCER ADA assay was developed using a tiered approach consisting of different subassays:
[1159] • Screening assay: high sensitivity to screen samples for potentially positive results.
[1160] • Confirmatory assay: high specificity to confirm the presence of ADAs.• Titration assay
[1161] The MAG003 TCER ADA assay used a homogeneous bridging strategy, in which the TCER was used as both capture and detection reagent while an ADA surrogate directed against the TCER was used as positive control (PC) (Figure 11). The anti-idiotype Ab generated by clone S (14C4B6B5) specifically directed against the MAG003 TCER recruiter domain was used a positive control (PC). The assay was developed with the MSD platform (Figure. 2, bottom) (MESO QuickPlex SQ120, MSD GOLD 96-well SA SECTOR Plate). The main analysis is performed using the MSD Discovery WorkBench software (version 4.0) and extra analyses are performed using MS Excel.
[1162] In the ADA screening assay, patient serum samples or controls were incubated with TCER Mastermix, consisting of biotinylated TCER and sulfo-tagged TCER. The MSD plate was blocked and washed, and the previous mix was incubated on this plate. After further washing, the plate was read and the presence of ADAs or PCs was detected. In the confirmatory ADA assay, high concentrations of unlabeled TCER were added to block the formation of the bridges such as the one shown in Figure 11. A certain level of signal reduction due to this blocking can confirm the specificity of the Abs (PC or ADAs) detected in the screening assay.
[1163] After MAG003 TCER ADA assay development, a fit-for-purpose validation was conducted and patient serum samples were analyzed with the validated assay. Furthermore, the assay was adapted for the detection of ADAs against PRAME004 TCER, and this assay was set up and used for preliminary PRAME004 TCER patient sample analyses. In both MAG003 TCER and PRAME004 TCER ADA assays, the same anti-idiotype Ab (clone S: 14C4B6B5) was used as PC. This antibody provided the advantageous assessment of performance parameters in set-up, development and validation, and was used for QCs during conduction.
[1164] 5 References
[1165] 1. Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific Ab targeting human claudin 6, Stadler et al., Sci. Transl. Med. (2024).
[1166] 2. Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101):
[1167] First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer, Tsimberidou AM et al., Cancer Immunol Res. (2023).
Claims
Claims1. A method for determining a level of a therapeutic protein in a sample,wherein the therapeutic protein comprises(i) an antigen binding site A specifically binding to a peptide that is in complex with a major histocompatibility complex (MHC) protein, and(ii) an antigen binding site B, andwherein the method comprisesa) incubating the sample comprising the therapeutic protein with the peptide-MHC complex specifically binding to the antigen binding site A of the therapeutic protein, b) incubating the therapeutic protein bound to the peptide-MHC complex with an anti- idiotypic antibody or fragment(s) thereof specifically binding to the antigen binding site B of the therapeutic protein, andc) detecting the anti-idiotypic antibody or the fragment(s) thereof bound to the therapeutic protein and thereby determining the level of the therapeutic protein in the sample.
2. The method of claim 1, wherein the method is used for determining the pharmacokinetic of the therapeutic protein.
3. The method of claim 1 or 2, wherein the therapeutic protein is a multispecific antigen binding protein, in particular a bispecific antigen binding protein.
4. The method of any one of claims 1 to 3, wherein the therapeutic protein comprises an antigen binding site A that is derived from a TCR, or is a TCR or fragment(s) thereof and that specifically binds to the peptide SEQID NO: lthat is in complex with an MHC protein or to the peptide SEQ ID NO: 2 that is in complex with an MHC protein; and / or wherein the therapeutic protein comprises an antigen binding site B that is derived from an antibody, or is an antibody or fragment(s) thereof and that specifically binds to a cell surface antigen of a human immune cells.
5. The method of any one of claims 1 to 4, wherein the peptide-MHC complex specifically binding to the therapeutic protein is immobilized on a solid phase, and wherein the method is performed on an immunoassay platform, preferably an Meso Scale discovery (MSD) platform.
6. The method of any one of claims 1 to 5, wherein the therapeutic protein comprises or consists ofa first polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 25 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 25 and comprising the CDRL1, CDRL2, CDRL3, CDR 1, CDR 2, and CDR 3 according to SEQ ID NOs: 8, 9, 10, 20, 21, and 22, respectively; and a second polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 26 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 26 and comprising the CDRal, CDRa2, CDRa3, CDRH1, CDRH2, and CDRH3 according to SEQ ID NOs: 17, 18, 19, 3, 5, and 6, respectively; or a first polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 35 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 35 and comprising the CDRL1, CDRL2, CDRL3, CDR|31, CDR|32, and CDR|33 according to SEQ ID NOs: 8, 9, 10, 30, 31, and 32, respectively; and a second polypeptide chain that comprises or consists of the amino acid sequence according to SEQ ID NO: 36 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 36 and comprising the CDRal, CDRa2, CDRa3, CDRH1, CDRH2, and CDRH3 according to SEQ ID NOs: 27, 28, 29, 3, 4, and 6, respectively.
7. An anti-idiotypic antibody or fragment(s) thereof comprising,a VH comprising(a) a CDRH1 comprising the amino acid sequence of SEQ ID NO: 40,(b) a CDRH2 comprising the amino acid sequence of SEQ ID NO: 41,(c) a CDRH3 comprising the amino acid sequence of SEQ ID NO: 42, anda VL comprising(a) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 43,(b) a CDRL2 comprising the amino acid sequence of SEQ ID NO: 44,(c) a CDRL3 comprising the amino acid sequence of SEQ ID NO: 45,and optionally wherein each of the CDRH1, the CDRH2 and the CDRH3, and the CDRL1, CDRL2, and CDRL3 comprises up to three amino acid substitutions.
8. The anti-idiotypic antibody or the fragment(s) thereof of claim 7, wherein the anti- idiotypic antibody or fragment(s) thereof comprisesa VL comprising or consisting of the amino acid sequence according to SEQ ID NO: 46 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 46 and comprising the CDRL1, CDRL2, and CDRL3 according to SEQ ID NOs: 43, 44, and 45, respectively; anda VH comprising or consisting of the amino acid sequence according to SEQ ID NO: 47 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 47 and comprising the CDRH1, CDRH2, and CDRH3 according to SEQ ID NOs: 40, 41, and 42, respectively;and wherein the anti-idiotypic antibody or the fragment(s) thereof specifically bind(s) to the antigen binding site B, wherein the antigen binding site B comprises(i) the VH comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 11, 12, 13 and 14; and(ii) the VL comprising an amino acid sequence of SEQ ID NO: 15 or SEQ ID NO: 16, and wherein the antigen binding site B specifically binds to an a / |3 T cell receptor (TCR) / CD3 complex.
9. The method of claims 1 to 6, wherein the anti-idiotypic antibody or the fragment(s) thereof of claim 7 or 8 is(are) used in step b) of claim 1.
10. An anti-idiotypic antibody or fragment(s) thereof comprising,a VH comprising(a) a CDRH1 comprising the amino acid sequence of SEQ ID NO: 50,(b) a CDRH2 comprising the amino acid sequence of SEQ ID NO: 51,(c) a CDRH3 comprising the amino acid sequence of SEQ ID NO: 52, anda VL comprising(a) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 53,(b) a CDRL2 comprising the amino acid sequence of SEQ ID NO: 54,(c) a CDRL3 comprising the amino acid sequence of SEQ ID NO: 55;ora VH comprising(a) a CDRH1 comprising the amino acid sequence of SEQ ID NO: 56,(b) a CDRH2 comprising the amino acid sequence of SEQ ID NO: 57,(c) a CDRH3 comprising the amino acid sequence of SEQ ID NO: 58, anda VL comprising(a) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 59,(b) a CDRL2 comprising the amino acid sequence of SEQ ID NO: 60,(c) a CDRL3 comprising the amino acid sequence of SEQ ID NO: 61;and optionally wherein each of the CDRH1, the CDRH2 and the CDRH3, and the CDRL1, CDRL2, and CDRL3 comprises up to three amino acid substitutions.
11. The anti-idiotypic antibody or the fragment(s) thereof of claim 10, wherein the anti- idiotypic antibody or fragment(s) thereof comprisesa VL comprising or consisting of the amino acid sequence according to SEQ ID NO: 62 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 62 and comprising the CDRL1, CDRL2, and CDRL3 according to SEQ ID NOs: 53, 54, and 55, respectively; anda VH comprising or consisting of the amino acid sequence according to SEQ ID NO: 63 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 63 and comprising the CDRH1, CDRH2, and CDRH3 according to SEQ ID NOs: 50, 51, and 52, respectively; ora VL comprising or consisting of the amino acid sequence according to SEQ ID NO: 64 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 64 and comprising the CDRL1, CDRL2, and CDRL3 according to SEQ ID NOs: 59, 60, and 61, respectively; anda VH comprising or consisting of the amino acid sequence according to SEQ ID NO: 65 or an amino acid sequence having at least 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 65 and comprising the CDRH1, CDRH2, and CDRH3 according to SEQ ID NOs: 56, 57, and 58, respectively;and wherein the anti-idiotypic antibody or the fragment(s) thereof specifically bind(s) to the antigen binding site A, wherein the antigen binding site A comprises a T cell receptor (TCR) alpha variable domain (Va) and a TCR beta variable domain (VP),wherein the antigen binding site A comprisesa Va comprising or consisting of the amino acid sequence according to SEQ ID NO: 23; anda VP comprising or consisting of the amino acid sequence according to SEQ ID NO: 24, and wherein the antigen binding site A specifically binds to the peptide SEQ ID NO: 1 that is in complex with an MHC protein.
12. A kit comprisingi) the anti-idiotypic antibody or the fragment(s) thereof of claim 7 or 8, and / or ii) the anti-idiotypic antibody or the fragment(s) thereof of claim 10 or 11, and optionallyiii) reagents for detecting, a solid phase coupled with the peptide MHC complex and / or a leaflet.
13. A method for determining a level of a therapeutic protein in a sample, wherein the anti- idiotypic antibody or the fragment(s) thereof of claim 7 or 8, and / or the anti-idiotypic antibody or the fragment(s) thereof of claim 10 or 11 are used in the method; or a method for determining a level of anti-drug antibodies against a therapeutic protein in a sample, wherein the anti-idiotypic antibody or the fragment(s) thereof of claim 7 or 8, and / or the anti-idiotypic antibody or the fragment(s) thereof of claim 10 or 11 are used in the method.
14. A method for determining a level of a therapeutic protein in a sample,wherein the therapeutic protein comprises(i) an antigen binding site A specifically binding to a peptide that is in complex with a major histocompatibility complex (MHC) protein, and(ii) an antigen binding site B, andwherein the method comprisesa) incubating the sample comprising the therapeutic protein with the anti-idiotypic antibody of claim 7 or 8 specifically binding to the antigen binding site B of the therapeutic protein; or with the anti-idiotypic antibody of claim 10 or 11 specifically binding to the antigen binding site A of the therapeutic protein, b) incubating the therapeutic protein bound to the anti-idiotypic antibody with the anti-idiotypic antibody specifically binding to the other antigen binding site of the therapeutic protein that was not bound by the anti-idiotypic antibody in step a), andc) detecting the anti-idiotypic antibody bound to the therapeutic protein and thereby determining the level of the therapeutic protein in the sample.
15. A method for determining a level of anti-drug antibodies against a therapeutic protein in a sample,wherein the therapeutic protein comprises(i) an antigen binding site A specifically binding to a peptide that is in complex with a major histocompatibility complex (MHC) protein, and(ii) an antigen binding site B, andwherein the method comprisesa) incubating the sample with (al) the therapeutic protein comprising a capturing reagent and (a2) the therapeutic protein comprising a labeling reagent, and b) detecting the therapeutic protein comprising the labeling reagent that is bound to the anti-drug antibody, and thereby determining the level of the anti-drug antibodies in the sample, and wherein the anti-idiotypic antibody of claim 7 or 8 is used as a control.
